Audited Financial Results for the year to 31 March 2022

Company Announcement
26 May 2022


AUDITED FINANCIAL RESULTS FOR THE YEAR TO 31 MARCH 2022
PACIFIC EDGE SEES GROWTH INITIATIVES GAINING TRACTION

HIGHLIGHTS:
 Annual operating revenue increased 49% to $11.4 million, while total revenue increased 33% to
$13.9 million
 Total laboratory throughput (TLT) of Cxbladder tests increased 46% to 23,086 tests, while
commercial tests (CT) increased 48% to 19,196 tests
 COVID-19 healthcare restrictions constrained growth. The easing of those restrictions and new
hires drove increases in TLT and clinician engagement in the final months of the financial year
 Net losses after tax increase to $19.8 million from $14.2 million, reflecting a 37% increase in
operating expenses to $33.7 million as the company invested to drive growth
 Initiatives of the Investment Program to drive customer retention, growth, and clinical evidence
generation relevant to guideline inclusion announced
 The initiatives of the Investment Program in FY23 will be phased in proportion to business
milestones to responsibly manage burn rate
 Pacific Edge is well funded with cash and cash equivalents and short-term deposits at $105.4
million at the end of the financial year, following the successful $103.5 million capital raise and
dual listing on the ASX in 2021


DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces
financial and operational results for the year to 31 March 2022 showing strong growth in the adoption of
its advanced genomic biomarker Cxbladder tests and early results suggesting initial traction can be
translated into faster growth.
It also announces new initiatives to drive the adoption of Cxbladder around the world. These include
increased investment in sales, marketing, innovation, and clinical evidence generation to advance the
case for the incorporation Cxbladder into globally relevant standards of care.
TEST VOLUMES
Total laboratory throughput (TLT) of Cxbladder for the year to 31 March 2022 rose 46% to 23,086 tests
from 15,814 tests in the prior financial year. Commercial test volumes increased 48% to 19,196, with the
increase reflecting the growing adoption of Cxbladder by physicians and healthcare organizations. These
results follow from the important milestones of obtain Medicare coverage and reimbursement from
Kaiser Permanente in 2020.
Pacific Edge Chief Executive Dr Peter Meintjes said: “In spite of the pandemic, the strong year-on-year
growth in Cxbladder test volumes demonstrates the value of Cxbladder to safely intensify or de-intensify
clinical workup for patients presenting with hematuria, resolve diagnostic dilemmas during hematuria
evaluation and monitor for the recurrence of urothelial cancer in post-treatment patients.

Company Announcement
26 May 2022

“Still, the last six months have been challenging. Restrictions in the healthcare sector have been more
severe and longer lasting than those imposed on the community at large, and this has limited engagement
with physicians ordering the tests and the organizations paying for them. It has also prevented patients
from engaging with their clinicians.
“With the easing of COVID-19 restrictions, the virus becoming endemic in our target markets, and recent
sales and marketing recruits beginning to hit their stride, we are seeing volumes begin to accelerate.
“Average weekly test throughput in the US from the start of April to last week were 455 tests per week,
a figure 25% higher than the average of the last year. These objective indicators, and the subjective
positive feedback from those regularly using Cxbladder, demonstrate that clinicians are gaining increasing
confidence in the use of Cxbladder earlier in the patient care pathway.
“They also show that Pacific Edge has an excellent opportunity to capitalize on existing traction in a very
large target market. The challenge before us is one of focus and execution to convert this enthusiasm and
momentum to greater recurring use of Cxbladder.”
FINANCIAL RESULTS
Total operating revenue - the income generated from Cxbladder test sales - increased 49% to $11.4 million
from $7.7 million over the same period last year. Total Income of $13.9m, an increase of 33% included
higher levels of research incentives and interest revenue, offset by a reduction of Covid-19 support of
$1.1 million.
Net loss after tax increased to $19.8 million from $14.2 million over the same period a year ago as Pacific
Edge accelerated its investment to drive the adoption of tests. Net operating expenses increased to $33.7
million from $24.7 million in the prior year.
Net operating cash outflow increased to $17.5 million from $13.6 million in the same period a year ago.
Pacific Edge remains well funded following the successful $103.5 million capital raising in 2021. Cash, cash
equivalents and short-term deposits stood at $105.4 million up from $23.1 million at the same time last
year.
REGIONAL PERFORMANCE
The US business is making steady progress, despite COVID creating barriers for in-person selling
opportunities – a key activity for growth and retention. Total Lab Throughput (TLT) for the year was up
59% to 18,864, while commercial tests increased 62% to 15,752.
Pacific Edge is working closely with Kaiser Permanente, the largest integrated healthcare provider in the
US with an estimated 12.5 million members covered by the Kaiser Health Plan, to roll Cxbladder out across
more sites and to educate more clinicians at each site in the use of Cxbladder. Kaiser Permanente
urologists familiar with Cxbladder through the evaluation continue to advocate for broader adoption
internally through an EMR integration with our support. In parallel with the EMR integration efforts, we
continue to focus our adoption efforts in Southern California adding new sites and ordering clinicians from

Company Announcement
26 May 2022

those involved in the initial evaluation. The adoption of Cxbladder Triage (CxbT) at Kaiser Permanente
enhances the case for its subsequent reimbursement by CMS.
Meanwhile we are working with the US Veterans Affairs (VA), the second largest integrated healthcare
provider in the US, to move from evaluation of our tests to widespread use across the more than nine
million veterans it covers. The completion of our DRIVE clinical study, which is examining the clinical utility
of Cxbladder in risk stratifying patients presenting with hematuria, is an important step towards this goal.
INITIATIVES OF THE INVESTMENT PROGRAM
“Since joining the company in January, my thoughts have coalesced around initiatives in three major areas
of the business that have the capacity to drive increases in long-term shareholder value,” Dr Meintjes
said.
“Firstly, we must continue to invest in technology and product innovation to maintain our leadership
position in urothelial cancer diagnostics. This means improving the performance characteristics of existing
products and expanding the context of use for Cxbladder to other segments of the patient care pathway.
“Secondly, we must augment that evidence through real world, real time clinical studies to establish
Cxbladder as a standard of care with clinicians, healthcare providers and funders ahead of inclusion of the
tests in globally relevant guidelines.
“And finally, having secured the support of these urological key opinion leaders, we must continue to
build awareness of the Cxbladder brand, taking our story to the wider clinician community and the patient
community.
“Today we are announcing initiatives that deliver on these priorities,” Dr Meintjes said.
Research and innovation
“We continue to evaluate new product concepts and cutting-edge technologies to determine if they can
be applied to the market and address an unmet clinical need. As we develop this technology, we will
continue to build a patent portfolio that we can subsequently develop into validated products for
commercialization. This may include other cancers, prognostics, or other non-cancer diseases where there
is strong biomarker signal in the urine – an existing core competency at Pacific Edge.
“The program will be staged and linked to the achievement of growth milestones. While we expect many
of these investments to quickly begin contributing to Pacific Edge’s business, we expect the aggregate of
these changes to drive long-term value creation and have greater contribution to revenue in the 2024
financial year and beyond,” Dr Meintjes said.
Evidence coverage and guidelines
Pacific Edge is accelerating its clinical evidence generation program to drive the inclusion of Cxbladder in
the American Urological Association (AUA), European Association of Urologists (EAU), and the National

Company Announcement
26 May 2022

Comprehensive Cancer Network (NCCN) guidelines. Simultaneously, Pacific Edge continues to drive
adoption in the absence of guidelines by demonstrating the utility of Cxbladder to urologists and uro-
oncologists through product evaluations, clinical studies partnerships, and the strength of our existing
clinical evidence.
Specifically, we are targeting evidence that demonstrates the value of Cxbladder in diagnosing
asymptomatic hematuria, in resolving diagnostic dilemmas (most commonly equivocal cystoscopy and
atypical cytology), detecting tumors in the upper tract, and reducing the patient burden of unnecessary
surveillance cystoscopies.
We want to ensure that Cxbladder is embedded from the earliest possible point and across the breadth
of the patient care pathway. The advancement of the LOBSTER study, which targets evidence to support
the inclusion of the test in the AUA standard of care announced to the NZX and ASX earlier this month, is
evidence of the program in action.
To support our evidence generation program, we have recently hired a VP of Medical Affairs, Dr Tamer
Aboushwareb, who will lead a team of 3-5 Medical Science Liaisons that will be technology and/or urology
specialists with a medical background.
The expanded team will increase our capacity to engage key opinion leaders on clinical studies; facilitate
faster and greater patient enrolment in studies; communicate our increasing body of clinical evidence to
drive the early adoption of Cxbladder and build momentum towards guideline inclusion. The team will
also work alongside our sales and marketing teams to assist with the adoption of Cxbladder by strategic
accounts; and work with the Clinical Science team to drive the generation of clinical utility evidence.
Adoption, retention, and revenue generation
We have a multi-pronged strategy for executing effectively in the market.
We are increasing the size of our sales team by up to 10 full time equivalents (FTE) to a planned total of
40 in FY24, as we know this direct sales model works and a controlled expansion will be a good use of
capital. Additionally, we have already deployed a Virtual Sales team to focus on rural clinicians and
patients and support the prospecting and onboarding for new accounts. The final number is dependent
on milestones during the course of the year. We are working with tenured Account Executives to lift
performance in established territories.
We are supporting market execution with investments in ancillary services, including the integration of
test ordering and resulting with healthcare providers’ electronic medical records (EMR) systems, driving
the adoption of patient in home sampling systems (PIHSS) and greater marketing investment and new
Managed Care initiatives.
Managed Care is an important element of customer care related to billing, explanation of benefits and
claims processing in the USA – it speaks strongly to the experience patients have when they engage with
Pacific Edge. “We want to drive towards seamless daily operations for healthcare providers, clinicians,

Company Announcement
26 May 2022

and patients as they order tests or collection kits, dispatch samples to our lab, and receive results,” Dr
Meintjes said.
Finally, we also plan to hire two FTE Strategic Account Sales people, who will work with the Virtual Sales
teams on service delivery at the largest healthcare providers and seek to onboard Cxbladder with new
providers.
Pacific Edge is investing to build the Cxbladder brand through partnerships with patient advocacy groups
such as the Bladder Cancer Advocacy Network in the US and New Zealand’s Cancer Society. Pacific Edge
intends these efforts to educate patients on their options, empower patients to request non-invasive
alternatives to cystoscopy and ultimately contribute to revenue.
We are continuing to develop our plans in Australia and in Asian markets. The advancement of clinical
study collaborations in Singapore and the impending publication of data on a Singaporean cohort
represent an important step towards this latter goal.
OUTLOOK
Chairman Chris Gallaher said the Board was pleased with the progress Pacific Edge has made, especially
when the results are considered against the backdrop of the difficult selling environment the company
has faced for much of the financial year.
“With the easing of COVID restrictions, the Board is pleased to see the investments the company has
made to accelerate its growth are beginning to deliver results. The support we are seeing for CxBladder
has reinforced our confidence in the investment program made possible by last year’s capital raising,” Mr
Gallaher said.
“We are also delighted to have been able to attract back to New Zealand our new Chief Executive Dr Peter
Meintjes, who over the last few months has quickly begun to build on the strong legacy left by his
predecessor David Darling.
“Peter has brought to the company a deep understanding of the diagnostics market, a clear vision of what
is required to drive success and great enthusiasm for the role. He has quickly established himself within
the business and is bringing the team along with him.
“On behalf of shareholders, we thank all of the Pacific Edge team for their efforts in what has been an
extremely challenging period.”
Finally, Mr Gallaher thanked Pacific Edge’s Directors for their commitment to the company over the last
year.
“With the appointment of the respected healthcare leader Tony Barclay to the Board in March, Pacific
Edge now has the full complement of skills and experience to provide the necessary oversight and
guidance as the company moves into its next phase of growth. It is an exciting time for the company,” Mr
Gallaher said.

Company Announcement
26 May 2022

Dr Meintjes said Pacific Edge expects its investment in innovation, evidence, people, and brand to drive
growth in test volumes and revenue, but it will also lift operating costs in the business.
“Based on the activities in R&D, clinical studies, and market execution, I am excited about the prospect
for the company. Pacific Edge continues to realize the opportunities I observed when I was evaluating the
opportunity to lead the company,” Dr Meintjes said.
“The company is focused on long-term shareholder value and is well positioned to deliver that over the
coming years. The steps we have announced today represent a significant focus of resources to deliver
on our potential. We look forward to further updating shareholders at our annual meeting in late July.”
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
For more information:
Investors Media
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: 022 032 1263

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and
commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of
recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through
its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder
evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection,
surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing
and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the
clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists
in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the
test online.

---

PACIFIC EDGE
INVESTOR PRESENTATION
FY 2022 RESULTS
26 MAY 2022

IMPORTANT NOTICE AND DISCLAIMER
ImportantNotice
This presentation has been prepared by Pacific Edge Limited (PEL) solely
to provide interested parties with further information about PEL and its
activities at the date of this presentation.
Information of a general nature
The information in this presentation is of a general nature and does not
purport to be complete nor does it contain all the information which a
prospective investor may require in evaluating a possible investment in
PEL or that would be required in a product disclosure statement,
prospectus or other disclosure documentfor the purposes of the New
Zealand Financial Markets Conduct Act 2013 (FMCA) or the Australian
Corporations Act. PEL is subject to a disclosure obligation that requires it
to notify certain material information to NZX Limited (NZX) and ASX
Limited (ASX) forthe purpose of that information being made available
to participants in the market and that information can be found by
visiting www.nzx.com/companies/PEBand
www2.asx.com.au/markets/company/PEB. This presentation should be
read in conjunction with PEL’s other periodic and continuous disclosure
announcements released to NZXand ASX.
Not an offer
This presentation is for information purposes only and is not an
invitation or offer of securities for subscription, purchase or sale in any
jurisdictionwhere such offer purchase or sale would not be permitted.
Not financial product advice
This presentation does not constitute legal, financial, tax, financial
product advice or investment advice or a recommendation to acquire
PEL securities, and has been prepared without taking into account the
objectives, financial situation or needs of investors. Before making an
investment decision, prospective investors should consider the
appropriateness of the information having regard to their own
objectives, financial situation and needs and consult an NZX Firm,
solicitor, accountant or other professional advisor if necessary.
Forward-looking statements
This presentation contains forward-looking statements that reflect PEL’s
current views with respect to future events. Forward-looking statements,
by their very nature, involve inherent risks and uncertainties. Many of
those risks and uncertainties are matters which are beyond PEL’s control
and could cause actual results to differ from those predicted. Variations
could either be materially positive or materially negative. The
information is stated only as at the date of this presentation. Except as
required by law or regulation (including the NZX Listing Rulesand ASX
Listing Rules), PEL undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. To the maximum extent permitted by law,
the directors of PEL, PEL and any of its related bodies corporate and
affiliates, and their respective officers, partners, employees, agents,
associates and advisers do not make any representation or warranty,
express or implied, as to the accuracy, reliability or completeness of such
information, or the likelihood of fulfilment of any forward-looking
statement or any event or results expressed or implied in any forward-
looking statement, and disclaim all responsibility and liability for these
forward-looking statements (including, without limitation, liability for
negligence).
Financial data
All dollar values are in New Zealand dollars unless otherwise stated. This
presentation should be read in conjunction with, and subject to, the
explanations and views of future outlook on market conditions, earnings
and activities given in the announcements relating to the results, and
report, for the twelve months ended 31 March 2022.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of
value and fractions in this presentation are subject to the effect of
rounding. Accordingly, the actual calculation of these figures may differ
from the figures set out in this presentation.
Past performance
Investors should note that past performance, including past share price
performance, cannot be relied upon as an indicator of (and provides no
guidance as to) future PEL performance, including future financial
position or share price performance.
Investment risk
An investment in securities of PEL is subject to investment risk and other
known and unknown risks, some of which are beyond the control of PEL.
PEL does not guarantee any particular return or the performance of PEL.
Disclaimer
None of PEL or PEL’s advisers or any of their respective affiliates, related
bodies corporate, directors, officers, partners, employees and agents,
have authorised, permitted or caused the issue, submission, dispatch or
provision of this presentation and, except to the extent referred to in
this presentation, none of them makes or purports to make any
statement in this presentation and there is no statement in this
presentation which is based on any statement by any of them.
To the maximum extent permitted by law, none of PEL and its advisers,
affiliates, related bodies corporate, nor their respective directors,
officers, partners, employees and agents makes any representation or
warranty, express or implied, as to the currency, accuracy, reliability or
completeness of information in this presentation; and none of them shall
have any liability (including for negligence) for:
• any errors or omissions in this presentation; or
• any failure to correct or update this presentation, or any other written
or oral communications provided in relation to this presentation; or
• any claim, loss or damage (whether foreseeable or not) arising from
the use of any information in this presentation or otherwise arising in
connection with this presentation or the information contained in it.
By receiving this presentation, you agree to the above terms and
conditions.

DR PETER MEINTJES
Chief Executive Officer
GRANT GIBSON
Chief Financial Officer

1. Highlights
2. About Pacific Edge
3. Operational performance
4. Framing our investment Program
5. Financial Performance
6. Outlook
7. Q&A
AGENDA

FY 22 HIGHLIGHTS: TEST VOLUMES ACCELERATE IN THE PIVOTAL US MARKET
$19.8M
NET LOSSAFTER
TAX
Global TLT of 23,086 tests
Commercial Tests increase
48% to 19,196 tests
Increase from $14.2M in
FY21 amid investment for
future growth
Operating revenue $11.4M
Total revenue $13.9M
$105.4M
CASH, CASH
EQUIVALENTS &
SHORT-TERM
DEPOSITS
Strong balance sheet
following $103.5M capital
raising in 2021
59%
US TESTING
VOLUMES (TLT*)
46%
GLOBAL TESTING
VOLUMES
(TLT*)
49%
GROWTH IN
OPERATING
REVENUE
US TLT of 18,864 tests
US Commercial Tests rise
62% to 15,572 tests
PACIFIC EDGE IS NOW SET TO BUILD ON
THIS SUCCESS WITH AN INVESTMENT
PROGRAM FRAMED BY THREE PILLARS
•RESEARCH AND INNOVATION
•EVIDENCE, COVERAGE AND GUIDELINES
•ADOPTION, RETENTION & REVENUE GENERATION
*TLT is the Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing

PACIFIC EDGE: AN OVERVIEW OF OUR BUSINESS AND THE OPPORTUNITY

Mission
To help improve people’s lives and
patient outcomes by providing leading
solutions for the early detection and
management of cancer.
Vision
A world where the early diagnosis and
better treatment of cancer is within
reach of everyone.
“Nobody should die of cancer”

PACIFIC EDGE AT A GLANCE
Commercial markets with
customers and clinical study partnerships
Markets with clinical study partnerships
USA
CANADA
Pacific Edge Diagnostics USA
Hershey, Pennsylvania
AUSTRALIA
NEW ZEALAND
SINGAPORE
Pacific Edge HQ, Dunedin
FROM IP DEVELOPMENT TO PATIENT
>2,000
1
Urologists
have ordered
Cxbladder in FY22
~300K
1
Annual
laboratory test
capacity
>80,000
1,2
Patients
have used
Cxbladder
86*
FTE people
(38 APAC,
48 USA)
1. Company data *As at 31 March 2022
2. Figures are cumulative across company history and represent unique patients
•IP: 4x patent families in urothelial cancer, with >80 patents including RNA
biomarkers and their analysis algorithms
•Cxbladder: Advanced genomic biomarker tests from a non-invasive urine
sample for the early detection and management of urothelial cancer
•Clinical Evidence: Peer-reviewed clinical validity and utility data that shows
Cxbladder outperforms Standard of Care (SoC)
•Reimbursement: Cxbladder tests reimbursed by Medicare and Kaiser Health
Plan
•Patient Empowerment: Non-invasive efficacious testing offers opportunity
for increased patient compliance with surveillance and management regimes

UROTHELIAL CANCER
IS A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
•Hematuria evaluation for suspected urothelial cancer has
high detection and surveillance costs
2
•Current American Urological Association guideline leads to recommendation
for >90%cystoscopy of patients presenting with hematuria
3
•Under guidelines in the US, 3.4 million patients should be worked
up for cystoscopy, but only 1 million undergo the procedure
4
•Only 40% of patients comply with existing standards of care due
to invasive and high-cost diagnostic procedures
5
1. Bray et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 3 cancers in 185 countries.CaCancer J Clin. 2018;68:394-424
2. Bottermanet al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21(18):1315-30.
3. WolduSL et al. (2021b) Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence." UrolOncol.
4. Kenigsberg, A, et al. The Economics of Cystoscopy: A MicrocostAnalysis, Urology 157: 29−34, 2021.
5. Schrag, D et al. Adherence to Surveillance Among Patients With Superficial Bladder Cancer JNIC, Volume 95, Issue 8, 16 April 2003.
TAM is the Total Addressable Market based on Pacific Edge estimates.
~550K
Annual cases
and growing
1
~200K
Annual
deaths
1
6TH
Most common
cancer in men
1
~70%
Recurrence
USA –TAM* US$3.5b
Americas (non-US) –TAM US$0.5b
EMEA (w/o most of Africa) –TAM US$1.4b
APAC (w/o China) –TAM US$2.2b

INTENSIFY/DE-INTENSIFY WORKUPS
ADJUDICATE DIAGNOSTIC DILEMMAS
MONITOR FOR RECURRENCE
SURVEILLANCE
(RDM
1
, TRM
2
, RECURRENCE)
PATIENT/DISEASE MANAGEMENT
(CLINICAL DECISION MAKING)
MOLECULAR DIAGNOSTICS VALUE CHAIN: PATIENT JOURNEY
GENOMIC SCREENING
(PERSONALIZED GENETIC RISK)
ASYMPTOMATIC SCREENING
(EARLY DETECTION)
GENETIC RISK
AT BIRTH
DISEASE
MANIFESTS
SYMPTOMS
ONSET
SURGICAL OR
THERAPEUTIC
INTERVENTION
1. RDM: Residual Disease Monitoring
2. TRM: Therapeutic Response Monitoring.

CXBLADDER IN THE PATIENT CARE PATHWAY
Primary Care Physician
Patient presents with
hematuria and clinician
cannot rule out cancer.
Patient referred to
urologist
Urologist
Current guidelines for
hematuria evaluation
recommend >90%get
cystoscopy
1
ahead of
diagnosis & treatment
Urologist
Monitor for recurrence
with cystoscopy,
frequency varies
according to patient
presentation
Typical
standard of
care on the
patient care
pathway
For use by
SPECIALISTS to detect
the presence of
urothelial cancer and
adjudicate diagnostic
dilemmas
For use in the PRIMARY CARE and SPECIALIST
settings to de-intensify hematuria workup or rule out
urothelial cancer (UC)
For use by SPECIALISTS
to monitor for recurrence
at a frequency proportional
to risk
TRIAGE
DETECT
MONITOR
Cxbladder
TRIAGE
(CxbT)
Cxbladder
DETECT
(CxbD)
Cxbladder
MONITOR
(CxbM)
VALUE PROPOSITION
Assists clinicians to safely de-intensify
hematuria evaluation from low incidence
populations
Sensitivity 95% / NPV 99%
Assists clinicians to adjudicatediagnostic
dilemmas (e.g. equivocal cystoscopy &
atypical cytology) in any patient population
Sensitivity 82% / Specificity 85% / NPV 97%
Assists clinicians in monitoring for UC
recurrence. Intended to reduce the
frequency of surveillance cystoscopy and
improve patient compliance
Sensitivity 93% / NPV 97%
Sensitivity: the likelihood of the test to be positive in a patient with the disease Specificity: the likelihood of the test to
be negative when the patient does not have the disease; NPV:the likelihood of a negative test being a true negative.
1
Woldu SL et al. (2021b) Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence." UrolOncol.

UROTHELIAL CANCER (UC) IN THE US MARKET
4TH
Most common
cancer in men
in the US
1
US$220,000
Average lifetime
cost
2
per patient
US$4.9B
Forecast direct costs
associated with
urothelial cancer
in 2020
2
The US has >55m
and >63m women
aged 50+
~7m
present with
Hematuria
2
~3.4m
require clinical
workup
2
>1.0m
patients receive
a cystoscopy
3
~83k
Annual cases of
bladder cancer
4
~800k
monitored for recurrence
Avg1.5CxbM/yr
5
US$3.5B
opportunity
6
(hematuria,
surveillance)
1
American Cancer Society, 2019 29
2
Presentation from Dr Sia Daneshmand (Director of Urologic Oncology and Clinical Research, USC) July 2019 2. NIH National Cancer Institute, 2021 4. Bladder Cancer Advocacy Network, 2017
3
Kenigsberg, A, et al. The Economics of Cystoscopy: A MicrocostAnalysis, Urology 157: 29−34, 2021.
4
National Cancer Institute 2021 forecast
5
Pacific Edge Estimate
6
Pacific Edge estimates at US$760/Per test
MORE THAN 4.6M TESTOPPORTUNITIES
VALUE PROPOSITION
Primary Care Physician
Urologist
Patient care
pathway
Cxbladder
TRIAGE
(CxbT)
Cxbladder
DETECT
(CxbD)
Cxbladder
MONITOR
(CxbM)

FY22 OPERATIONAL PERFORMANCE

6,573
5,591
9,192
7,054
7,385
10,004
-
5,000
10,000
15,000
20,000
25,000
FY20FY21FY22
Test volumes
1H2H
8,147
6,864
11,136
8,714
8,950
11,950
-
5,000
10,000
15,000
20,000
25,000
FY20FY21FY22
Test volumes
1H2H
46%
GLOBAL: COMMERCIAL TESTS GROWING STRONGLY AS US ACCELERATES
19%
56%
25%
FY22 Testing Volumes (TLT) by Type
24%
53%
23%
FY21 Testing Volumes (TLT) by Type
PEL: Global Commercial Testing Volumes
PEL: Global Testing Volumes (TLT*)
Total Lab Throughput (TLT) has increased 46% to 23,086 tests in FY22
•Stronger US growth despite COVID continuing to impact sales efforts
throughout the financial year
•Account Executives hired in in the US during FY22 are moving to
tenured and improving contribution
•Growth in CxbladderDetect in test mix reflects growing US test
volumes
Triage Detect MonitorTriage Detect Monitor
23,086
15,814
16,861
19,196
12,976
13,627
48%
*TLT is the Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing

6,251
4,924
8,983
6,989
6,934
9,881
-
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
FY20FY21FY22
Test volume
1H2H
11,858
18,864
13,240
AMERICAS: SALES ACTIVITY AND INDICATORS
Distribution of Current
U.S. Customers
Pacific Edge Diagnostics
USA, Hershey,
Pennsylvania
•Stronger US growth (59%) despite COVID continuing to affect sales efforts
throughout the financial year
•Sales activity is clustered predominantly in urban population centres
•Continued to increase the number of US Account Executives during FY22,
with 23 at the end of March 2022, up from 18 at the end March 2021
1
Americas’ Testing Volume (TLT)
Americas’ Commercial Testing represent 84%of FY22 volumes
59%
1
These Account Executives were supported by three Regional Sales Directors, who have been in place over the entire financial year.

AMERICAS: COVID IMPACT AND RECOVERY
•Number of reported tests/week has tracked COVID waves, and is showing promising increasing signs
•Number of unique ordering clinicians has tracked COVID waves, and is showing promising increasing signs
Americas ‘Four-week Trailing’ Testing Volumes (TLT)Americas Monthly Ordering Clinicians
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Jan-20
Feb-20
Mar-20
Apr-20
May-20
Jun-20
Jul-20
Aug-20
Sep-20
Oct-20
Nov-20
Dec-20
Jan-21
Feb-21
Mar-21
Apr-21
May-21
Jun-21
Jul-21
Aug-21
Sep-21
Oct-21
Nov-21
Dec-21
Jan-22
Feb-22
Mar-22
Apr-22
‘Four-week Trailing’ test volumes
0
100
200
300
400
500
600
Jan-20
Feb-20
Mar-20
Apr-20
May-20
Jun-20
Jul-20
Aug-20
Sep-20
Oct-20
Nov-20
Dec-20
Jan-21
Feb-21
Mar-21
Apr-21
May-21
Jun-21
Jul-21
Aug-21
Sep-21
Oct-21
Nov-21
Dec-21
Jan-22
Feb-22
Mar-22
Apr-22
Ordering Clinicians

AMERICAS: KEY PAYORS ALREADY ACTIVATED
•The Kaiser Health Plan covers over 12.5m members, with >85% of those members in California
•Following internal utility evaluation, clinic-by-clinic rollout continues starting in Southern
California where the test was evaluated
•Volume growth is steady, and is expected to increase after Electronic Medical Record (EMR)
integration. This is viewed as a marathon, not a sprint
•CxbladderTriage adoption at Kaiser enhances the case for reimbursement by CMS
•The Veterans Health Administration (VHA) within the Department of Veterans Affairs (VA) is the
second largest integrated healthcare system in the US serving >9m veterans each year
•The DRIVE clinical study is an important engagement with VA urologists to determine utility in a
cohort of VA patients
•As the study nears completion, Pacific Edge expects to slowly migrate the study sites and other VA
sites to commercial adoption as part of a site-by-site rollout
•CxbladderTriage adoption at the VA enhances the case for reimbursement by CMS
•Centers for Medicare and Medicaid Services (CMS) covers more than 61.5m US citizens over 65
and people on low incomes
•Average age of patients presenting with hematuria is over 70 years old. Consequently, the payor
landscape skews towards Medicare with more than two thirds of our patient population covered
by Medicare
•Focus is on selling to urologists, who order Cxbladder tests based on medical necessity

1,896
1,940
2,153
1,725
2,016
2,069
-
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
FY20FY21FY22
Test volumes
1H2H
APAC: NEW ZEALAND AT THE FOREFRONT WITH ADOPTION BY PRIMARY CARE
•More than 70% of New Zealand’s population are already
covered by individual DHB agreements. Further market
adoption in New Zealand is expected to be slower that
other regions with APAC
•COVID restrictions impacted our sales efforts leading to a
slower rate of growth in New Zealand during FY22
•The upcoming consolidation of the DistrictHealth Boards in
New Zealand provides an opportunity for greater coverage
and more consistent usage of Cxbladder
•Promoting additional hospitals to utilize Cxbladder in
Primary Care (aka the “Canterbury Model”) provides an
opportunity for additional growth in New Zealand
•Early commercial testing volume received from Northern
Health in Melbourne with nineother Australian hospitals
triallingCxbladder
•Singapore clinical studies completed enrolment; business
case underway to determine go-to-market approach
Commercial tests represent 82%of FY22 volumes
3,956
4,222
7%
APAC Test Volumes (TLT)
3,621

THE FUTURE: PACIFIC EDGE INVESTING FOR GROWTH

FRAMING OUR INVESTMENT PROGRAM
Mission
To help improve
lives and patient
outcomes by
providing leading
solutions for the
early detection
and management
of cancer.
OUR PEOPLE
OUR PROCESSES
OUR IP, KNOWLEDGE
AND EXPERIENCE
OUR CLINICAL STUDIES
PARTNER SITES
OUR INVESTORS
EARLY DETECTION AND
CLINICALLY ACTIONABLE CARE
INNOVATION PIPELINE FOR
CLINICAL APPLICATIONS
INCLUSIVE WORKPLACE
DRIVEN BY OUTCOMES
INCREASED LONG-TERM
SHAREHOLDER VALUE
ADOPTION,
RETENTION AND
REVENUE
GENERATION
EVIDENCE,
COVERAGE AND
GUIDELINES
RESEARCH
AND
INNOVATION
Vision
A world where the early
diagnosis and better treatment
of cancer is within the reach of
every patient
A DIVERSE AND INCLUSIVE VALUES-DRIVEN CULTURE WHERE ALL EMPLOYEES CAN GROW AND THRIVE.
OUR FOUNDATIONS
EXCELLENT PATIENT EXPERIENCE
AND ACCURATE RESULTS
INPUTSOUTPUTS

1) RESEARCH AND INNOVATION:
UNDERSTANDING THE ENTIRE COMMERCIALISATION PATHWAY
RESEARCH &
INNOVATION
INTELLECTUAL
PROPERTY
TECHNOLOGYPRODUCT
COMMERCIALISATION
FOCUS AREAS:
1. Evaluate ‘product concepts’ to address unmet clinical needs through market research and scientific/clinical advisory boards
2. Evaluate cutting-edge technologies to meet the market requirements of desired product concepts
3. Continue to build a patent portfolio for novel clinical applications of cutting-edge molecular technologies
4. Turn patented technology into clinically-validated molecular diagnostic tools that address an unmet clinical need

RESEARCH AND INNOVATION: DRIVING IP TO TECHNOLOGY
FY22 ACHIEVEMENTS
•Publication of TDR study covering CxbR, alone and in
combination
1
•Important insights on distinguishing High Impact
Tumours
•More R&D needed to develop CxbR as a clinically
actionable test
•Singapore Observational Study –patient enrolment
complete despite COVID disruption
FY23 FOCUS
•Singapore Observational Study
•Data analysis complete. Publication pending
•Explore market potential of various product concepts
including:
•Prognostics or companion diagnostics in urology
•Adjacent disease (with molecular signal in the urine)
•Enhance Pacific Edge’s information infrastructure
1.Raman, D et al The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and
Priority Evaluation of Patients at Risk for Urothelial Carcinoma. Journal of Urology, Vol. 206, 1380-1389, December 2021
$190M
Accumulated
investment in
Cxbladder over
10+ years
4
Patent families
spanning
RNA and analysis
algorithms
KEY IP
Ability to stabilise
RNA/DNA and
determine gene
expression
signatures in
urine

2) EVIDENCE, COVERAGE AND GUIDELINES: CHANGE CLINICAL PRACTICE
FOCUS AREAS:
Generate high-quality clinical validation and utility evidence
through clinical studies
Use Clinical Utility evidence to:
•Drive the adoption of Cxbladder by clinicians,
insurers and hospitals ahead of guideline inclusion
•Pursue inclusion of Cxbladder in globally-relevant
standards and guidelines of clinical care across the
breadth of patient pathways
•Foster trusted relationships with key opinion
leaders, relevant uro-oncology centres of
excellence, professional societies and patient
advocacy networks to drive a broader awareness
and demand for Cxbladder
•Develop the scientific and clinical credibility of the
Cxbladder brand
EVIDENCE
COVERAGE AND
GUIDELINES

GLOBAL GUIDELINES PIVOTAL TO THE WIDESPREAD ADOPTION OF CXBLADDER
Recognition in national guidelines deepens and accelerates commercial use of Cxbladder tests and entrenches
coverage by nationally relevant healthcare institutions.
•Most influential and largest
urologicalassociation in the world
•U.S. based -23,000 members worldwide.
•Standards of care relevant to Cxbladder:
•Hematuria and micro-hematuria
management
•Non-muscle invasive bladder
cancer (NMIBC). (Standard makes
an allowance for the use of
biomarkers in surveillance)
•Guidelines reviewed as new evidence
emerges
•Pacific Edge can influence this process by
publishing new clinical evidence
www.auanet.org
•Leading urologic authority in Europe
•Netherlands-based, 18,000 members
•Standards relevant to Cxbladder
•Non-muscle invasive bladder
cancer (NMIBC)
•Guidelines loosely followed in New
Zealand, Australia and Singapore,
but localised at a national and
regional level
•Guidelines recently reviewed with
favourable biomarkerlanguage and are
updated regularly
www.uroweb.org
•US-based not-for-profit alliance of 32
leading US cancer centres
•Bladder cancer standard suggests
biomarkers may be considered during
surveillance of high-risk non-muscle-
invasive bladder cancer
•Guidelines reviewed annually
www.nccn.org

STRENGTHENING THE CASE FORCXBLADDER IN KEY GUIDELINES
BEFORE
INCLUSION
We use clinical validity and utility evidence to
attract interest from opinion-leadingclinicians,
and payers, drive early adoption ofCxbladder
and build momentum for guideline inclusion
INCLUSION
AFTER
INCLUSION
We use clinical validity and utility
evidence to strengthen the language in
guidelines supporting the use of
Cxbladder to expand patient types
eligible for testing
Review

CLINICAL EVIDENCE GENERATION TOWARDS GUIDELINE INCLUSION
(1/2)
STUDYAIMLOCATIONS ENROLLED
SITES*
STATUS**
US Primary studyProspective, single-arm, observational study to develop clinical evidence for Cxbladder tests in
facilitating early detection, intensifying or de-intensify hematuria evaluation and assistance in
adjudicating equivocal cystoscopy
USA12/12 Enrolment complete
Analysis complete
Publication pending
Singapore StudyProspective, single-arm, observational study to develop clinical evidence for Cxbladder tests in
facilitating early detection, intensifying or de-intensify hematuria evaluation and assistance in
adjudicating equivocal cystoscopy
Singapore4 / 4Enrolment complete
Analysis complete
Publication pending
STRATIFY
(formerly RCT)
Safe Testing of Risk for AsymptomaTIc Microhematuria, Females & Younger patients
Demonstrate the clinical utility of Cxbladder using a prospective, two-arm randomizeddesign to
safely risk-stratify patients and rule out from further hematuriaevaluation
•Safely risk stratifying patients in order to rule out from cystoscopy
•Demonstrate the clinical utility of Cxbladder against the AUA guidelines
USA
Canada
10 / 11 Recruitment re-started after
COVID-related delays
Full data collected2023 Q4
DRIVE (formerly
VA Study)
Detection and RIsk Stratification in VEterans Presenting with Hematuria
Prospective, single-arm, observational study to demonstrate the performance and utility of
Cxbladder tests in risk stratifying Veterans presenting with hematuria
•Demonstrate performance with Veterans and contribute to commercial adoption of
Cxbladder for use with Veterans
•Pivotal for the adoption of Cxbladder by Veterans Affairs but relevant to the AUA
•Recruitment re-started after COVID-related delays
•Targeting inclusion of all veterans presenting for evaluation of hematuria
VA Sites (USA) 7 / 11 Study expanded to get more data on
low-risk patients
Full data collected mid 2025
*Estimated number of enrolled sites
**All dates are best-case estimates and subject to change

STUDYAIMLOCATIONS ENROLLED
SITES*
STATUS**
DEDUCT
DEtection of Disease in the Upper traCT
Prospective, single-arm, observational study to validate performance of Cxbladder for the
detection of urothelial carcinoma (UC) in the upper tract (UTUC)
•Evaluate Cxbladder to safely avoid ureteroscopy
•Safely risk stratify patientssuspected to have UTUC and avoid unnecessary ureteroscopy
and radiation exposure through imaging
•Targeting inclusion of Cxbladder utility for UTUC in AUA guidelines
USA0 / 4Pilot data analysed in early 2024 –
decision point to expand the study
LOBSTERLOngitudinalBladder Cancer Study for Tumor REcurRence
Prospective, single-arm, observational study to evaluate the performance characteristics and
clinical utility of CxbMin a new surveillance protocol vs standard of care over four visits
•Safely risk stratify patients under surveillance for recurrence of UC
•Safely alternate CxbMwith cystoscopy for intermediate and high-risk patients under
surveillance for recurrence of UC
•Targeting AUA guidelines inclusion for biomarkers as an alternative to cystoscopy in a
surveillance setting
USA (including
some VA sites)
Australia
2 / 10 First patient expected in 2022 Q2
MONSTER
MONitoring Study of post-Treatment Effectiveness for Residual Disease
Single-arm, observational study to validate the performance characteristics of Cxbladder
against white light cystoscopy during surveillance of UC
•Christchurch District Health Board study to measure tumor burden
•To safely risk stratify patients for residual disease prior to the 6-week re-resection for high
grade patients or the 3-month flexible cystoscopy check for all patients
NZ0 / 1In planning, once pilot analysed then
consider expansion to USA
CLINICAL EVIDENCE GENERATION TOWARDS GUIDELINE INCLUSION
(2/2)
*Estimated number of enrolled sites
**All dates are best-case estimates and subject to change

3) ADOPTION, RETENTION AND REVENUE GENERATION
ADOPTION,
RETENTION AND
REVENUE
GENERATION
FOCUS AREAS:
1. Diversify sales process to target Strategic
Accounts differently, including education and
Key Opinion Leader (KOL) engagement activities
by our Medical Affairs team
2. Drive protocolized adoption of Cxbladder at the
earliest point in the patient care pathway
3. Increase event marketing, sponsorship and
marketing communications to amplify our
clinical evidence generation within the urology
and oncology communities
4. Establish “in-network” or contracted
relationships for the reimbursement of
Cxbladderwith government healthcare funders
and private payors
5. Empower patients through patient awareness
and patient advocacy initiatives through
established societies and our Cxbladder website

CAPITALIZING ON EARLY MOMENTUM
(1/2)
AMERICAS INITIATIVES
•Direct Sales Force :
•Up to 9 additional Account Executives and 1
Regional Sales Director to be added to the sales
team taking the total to up to 40*
•New MarkeƟng & Sales Support Managers (+2 FTE)*
•New Virtual Sales Team (up to +5 FTE) * to enhance
the customer experience and streamline test
ordering and results delivery
•Strategic Accounts Sales personnel (up to +2 FTE)
•Medical Affairs Team:
•VP Medical Affairs, leading a team of Medical
Science Liaison (MSL) (3-5 FTE)*
•MSLs are educators and experts on clinical, scientific
and medical matters relevant to products and
urology in general
•Drive Key Opinion Leader (KOL) engagement with
speakers’ bureaus, advisory boards and similar
•Targeting podium presentations of our clinical
evidence at major conferences
13,790
Practicing
urologists
1
1,900
Large urology
group practice
sites
2
>2,000
Clinicians that
used Cxbladder
in FY22
3
TARGET US RELATIONSHIPS
1
American Urological Assn Census 2021,
2
BHN Network
3
Company data
*All planned hires subject to achievement of business milestones.

CAPITALIZING ON EARLY MOMENTUM
(2/2)
AMERICAS INITIATIVES
•Marketing Activities:
•Conference podiums, presentations, posters
•Conference adverƟsing/sponsorship
•Increased and targeted marcom activities
•Customer Experience:
•Electronic Medical Records (EMR) integration–
streamlining customer ordering and reporting.
•PIHSS –continued promotion of our patient in-home
sampling system
•Managed Care –focus on simplifying EOB, billing and
claims processing
APAC INITIATIVES
•Adding remaining New Zealand DHBs, driving Cxbladderto
primary care.
•Market development through clinical studies in Australia,
Singapore
•Commencement of commercial revenue in Australia
•New APAC business development manager (+ 1FTE)
50
Urology
conferences
across the US
and APAC
4 + 36
Planned total
Sales Execs*
5
New virtual
sales team
members*
ENGAGING WITH CLINICIANS
AND CUSTOMERS
1
American Urological Assn Census 2021,
2
BHN Network
3
Company data
*36 Account Execs and 4 Regional Sales Directors. Executives All planned hires subject to achievement of business milestones.

PATIENTS: BUILDING THE CX BRAND AND ADVOCACY
UNITED STATES OF AMERICA
The Bladder Cancer Advocacy Network (BCAN) represents the voice of the patient
in the USA:
•Dedicated to advancing research and supporting those impacted by the disease
•Large and growing community of patients, caregivers, survivors, advocates,
medical and research professionals
•Coordinate networking, knowledge sharing, and fundraising events throughout
year
•Provide a range of educational resources and support services for patients and
caregivers
Planned partnership activity:
•Sponsorship of Walk to End Bladder Cancer events aroundthe country
andthought leadership and networking events
•Co-development of leading patient resources
Evolution of Cxbladder.com as a resource hub for patients and caregivers:
•Growing library of clinical and care-focused articles designed to design
toaddresstopics of interest and common questions

PATIENTS: BUILDING THE CX BRAND AND ADVOCACY
APAC
Cancer Society New Zealand:
•New Zealand's leading organisation dedicated toreducing cancer incidence,
and care
•Work closely with communities and decision makersto provide leadership
around cancer control
Planned partnership activity:
•Collaboration on patient resources.Starting In May 2022 (Bladder Cancer
Awareness Month) this will focus on educational video to promoteawareness
of bladder cancer symptoms and risk factors among high-risk groups
Evolution of Cxbladder.comas a resource hub for patients and
caregivers:
•Growing library of clinical and care-focused articles designed to design to
addresstopics of interest and common questions

GRANT GIBSON
Chief Financial Officer

$1,425
$2,033
$2,285
$3,326
$5,378
$1,975
$1,784
$2,085
$4,375
$6,067
$-
$2,000
$4,000
$6,000
$8,000
$10,000
$12,000
$14,000
FY18FY19FY20FY21FY22
$(000)
1H2H
7%
93%
ROWAmericas
THE US AND TEST VOLUME GROWTH DRIVING REVENUES
•Operating revenue for FY22 49% up on the prior year to $11.4m
•Seeing an acceleration in test volumes with new hires and easing of COVID
restrictions (strong growth from March ’22 to May ’22)
•US continuing to contribute an increasing share of revenue
49%
$11,445
$7,701
$
4,370
$3,817$3,400
11%
89%
ROWAmericas
FY22
FY21
Pacific Edge Operating Revenue
Regional Revenue Split

ACCELERATING INVESTMENT TO CAPTURE THE US OPPORTUNITY
•Operating revenue growth of 49%
•Operating expenses up 37%, with sales
and marketing making up 56% of this
growth as we invest infuture growth
•Cash receipts rise strongly year on year
(up 62%), as reimbursement rates
continue to increase
•Strong balance sheet following the
$103.5m capital raise in September /
October 2021
Year to 31 March
2022
$000
2021
$000
Variance
$000
Change
%
Operating revenue11,445 7,701 3,74449%
Total revenue13,878 10,439 3,43933%
Operating expenses(33,666) (24,662) (9,004)37%
Total comprehensive loss (19,674) (14,177) (5,497)39%
Cash receipts from
customers
10,942 6,747 4,19562%
Net operating cash
outflow
(17,552)
(13,570) (3,982)29%
Net cash, cash
equivalents and short-
term deposits
105,412 23,129 82,283 356%

OPERATING COSTS RISING IN LINE WITH CAPITAL RAISING PROGRAM
Operating Expenses
Year to 31 March
2022
$000
2021
$000
Variance
$000
Change
%
Laboratory Operations6,4985,466 1,03219%
Research5,1354,58455112%
Sales and marketing14,2779,202 5,07555%
General and
administration
7,7565,410 2,34643%
Total operating expenses 33,666 24,662 9,00437%
INVESTING IN FY23 TO DELIVER IN FY24
•Operating expenses increase 37% to
$33.7m
•Majority of expansion (56%) is in sales and
marketing as we increase Account
executives in the US, and COVID restrictions
ease and face to face meetings
recommence
•Laboratory operating expenses have
increased in line with volumes
•R&D expenditure rising with clinical trial
expansion and investment for long-term
growth
•G&A up by $2.3m with capital raising and
ASX listing adding $0.8m
•Expect increase in the coming year as
investment for growth continues

DR PETER MEINTJES
Chief Executive Officer

OUTLOOK: INVESTING FOR
LONG TERM GROWTH
•Pacific Edge expects its investment in innovation, evidence,
people, and brand to drive growth in test volumes and revenue
•We also expect that the selling environment, including
international travel will improve with COVID restrictions easing
as the disease becomes endemic
•Consequently, Pacific Edge is excited and optimistic that the
investment priorities outlined here are well aligned with long-
term shareholder value, and we remain well-positioned to
deliver that over the coming years

Q&A

APPENDIX

PACIFIC EDGE: A HISTORY OF RESEARCH-LED INNOVATION AND GROWTH
2001
2001
Pacific Edge
established
2001-2006
The era of the
Microarray. Cancer
biomarker panel
exploration
2007
2007
Commercial
pivot to focus
on urothelial
cancer
diagnostics
2008
Holyoake et al: Urine-
based RNA detection
of urothelial cancer
Clin Cancer Res
2008
2011
2011
Pacific Edge
Diagnostics
New Zealand
(PEDNZ)
established
2012
2012
O’Sullivan et al:
Cxbladder Detect
performance validation
Journal of Urology
Dec 2012
Launch of Pacific Edge
Diagnostics USAand
CxbD
2013
Mar 2013
PEDUSA receives
CLIA
accreditation
May 2013
First commercial
sale (CxbD) for
PEDNZ
Mar 2013
First commercial
sale (CxbD) for
PEDUSA
2014
Dec 2014
Launch of Cxbladder
Triage
2015
Mar 2015
Kavalieris et al:
CxbT performance
validation BMC
Urology
Dec 2015
Launch of
Cxbladder Monitor
2016
Nov 2016
Clinical trials
commence in
Singapore
2018
Feb 2018
CxbT adopted into
Canterbury
Community Health
Pathways with
primary care
referral
2019
Aug 2019
Konety et al: Clinical
Utility of CxbD in
adjudicating atypical
cytology and
equivocal cystoscopy
European Urology
2020
Apr 2020
Patient in-home sampling
initiated in the US
Jun 2020
Kaiser Permanente,
approves commercial use
of Cxbladder
Jul 2020
CMS confirms
reimbursement of
Cxbladderat $760/test
2021
Aug 2021
Cxbladder reaches
70% public
healthcare
coverage in NZ
Oct 2021
PEB raises $103.5m
(~US$72.5m)
Dec 2021
First commercial
sale of Cxbladder in
Australia

For further information:
Peter Meintjes
Chief Executive Officer
email: peter.meintjes@pelnz.com
Grant Gibson
Chief Financial Officer
email: grant.gibson@pelnz.com
Pacific Edge
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
email: investors@pacificedge.co.nz
www.pacificedgedx.com

---

22
CONSOLIDATED
FINANCIAL
STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2022

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
2
Consolidated Financial Information
Consolidated Statement of Comprehensive Income 3
Consolidated Statement of Changes in Equity 4
Consolidated Balance Sheet 5
Consolidated Statement of Cash Flows 6
Notes to the Consolidated Financial Statements 7
Independent Auditor’s Report 36
Company Directory 40

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
3
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the year ended 31 March 2022
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements
Notes
2022
($000)
2021
($000)
REVENUE
Operating Revenue 5 11,445 7,701
Total Operating Revenue 11,445 7,701
Other Income5 1,691 2,386
Interest Income9 549 351
Foreign Exchange Gain 193 1
Total Revenue and Other Income 13,878 10,439
OPERATING EXPENSES
Laboratory Operations 6,498 5,466
Research6 5,135 4,584
Sales and Marketing 14,277 9,202
General and Administration7 7,756 5,410
Total Operating Expenses 33,666 24,662
NET LOSS BEFORE TAX (19,788) (14,223)
Income Tax Expense16--
LOSS FOR THE YEAR AFTER TAX (19,788) (14,223)
Items that may be reclassified to profit or loss:
Translation of Foreign Operations 114 46
TOTAL COMPREHENSIVE LOSS attributable to
equity holders of the Company
(19,674) (14,177)
Earnings per share for loss attributable to the equity
holders of the Company during the year
Basic and Diluted Earnings per share3 (0.026) (0.020)

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
4
Share
Capital
Accumulated
Losses
Share
Based
Payments
Reserve
Foreign
Currency
Translation
Reserve
Total
Equity
Notes($000)($000)($000)($000)($000)
Balance as at 31 March 2020 165,423 (156,242) 4,542 781 14,504
Loss after tax- (14,223)-- (14,223)
Other Comprehensive Income--- 46 46
TOTAL COMPREHENSIVE LOSS
attributable to equity holders of the
Company
- (14,223)- 46 (14,177)
Transactions with owners in their
capacity as owners:
Issue of Share Capital18 21,962 --- 21,962
Share Based Payments - Employee
Remuneration
8 284 --- 284
Share Based Payment - Employee
Share Options
8 2,636 404 (504)- 2,536
Balance as at 31 March 2021 190,305 (170,061) 4,038 827 25,109
Balance as at 31 March 2021 190,305 (170,061) 4,038 827 25,109
Loss after tax- (19,788)-- (19,788)
Other Comprehensive Income--- 114 114
TOTAL COMPREHENSIVE LOSS
attributable to equity holders of the
Company
- (19,788)- 114 (19,674)
Transactions with owners in their
capacity as owners:
Issue of Share Capital18 99,622 --- 99,622
Share Based Payments - Employee
Remuneration
8 172 --- 172
Share Based Payment - Employee
Share Options
8 4,040 - (893)-3,147
Balance as at 31 March 2022 294,139 (189,849) 3,145 941 108,376
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the year ended 31 March 2022
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
5
CONSOLIDATED BALANCE SHEET
As at 31 March 2022
Notes
2022
($000)
2021
($000)
CURRENT ASSETS
Cash and Cash Equivalents935,412 4,129
Short Term Deposits9 70,000 19,000
Receivables10 4,012 2,866
Inventory11 1,007 790
Other Assets12 1,183 557
Total Current Assets 111,614 27,342
NON-CURRENT ASSETS
Property, Plant and Equipment13 1,404 688
Right of Use Assets23 1,830 2,977
Intangible Assets14 434 177
Total Non-Current Assets 3,668 3,842
TOTAL ASSETS 115,282 31,184
CURRENT LIABILITIES
Payables and Accruals17 4,983 3,197
Lease Liabilities23 1,072 1,098
Total Current Liabilities 6,055 4,295
NON-CURRENT LIABILITIES
Lease Liabilities23 851 1,780
Total Current Liabilities 851 1,780
TOTAL LIABILITIES 6,906 6,075
NET ASSETS 108,376 25,109
Represented by:
EQUITY
Share Capital18 294,139 190,305
Accumulated Losses (189,849) (170,061)
Share Based Payments Reserve 3,145 4,038
Foreign Translation Reserve 941 827
TOTAL EQUITY 108,376 25,109
FURTHER INFORMATION
Net Tangible Assets per share ($) 0.133 0.034
For and on behalf of the Board of Directors dated the 25th day of May 2022:
Director Director
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
6
CONSOLIDATED STATEMENT OF CASH FLOWS
For the year ended 31 March 2022
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements
Notes
2022
($000)
2021
($000)
CASH FLOWS TO OPERATING ACTIVITIES
Cash was provided from:
Receipts from Customers10,942 6,747
Receipts from Grant Providers 1,413 1,059
Interest Received 365 271
12,720 8,077
Cash was disbursed to:
Payments to Suppliers and Employees30,198 21,643
Net GST cash outflow 74 4
30,272 21,647
Net Cash Flows To Operating Activities20 (17,552) (13,570)
CASH FLOWS TO INVESTING ACTIVITIES:
Cash was provided from:
Proceeds from Short Term Deposits51,837 23,081
51,837 23,081
Cash was disbursed to:
Purchase of Short Term Deposits 102,837 29,052
Capital Expenditure on Plant and Equipment 713 270
Capital Expenditure on Intangible Assets 413 108
103,963 29,430
Net Cash Flows To Investing Activities(52,126) (6,349)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash was received from:
Ordinary Shares Issued18 103,488 22,000
Exercising of Share Options 2,306 1,500
105,794 23,500
Cash was disbursed to:
Repayment of Leases - Principal231,1471,143
Repayment of Leases - Interest23126107
Issue Expenses18 3,865 38
5,138 1,288
Net Cash Flows From Financing Activities 100,656 22,212
Net increase in Cash Held30,978 2,293
Add Opening Cash Brought Forward 4,129 1,755
Effect of exchange rate changes on net cash 305 81
Ending Cash Carried Forward935,412 4,129

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
7
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
1. ACCOUNTING POLICIES
SUMMARY OF ACCOUNTING POLICIES
Reporting Entity
The consolidated financial statements (hereafter referred to as the ‘financial statements’) presented for the year
ended 31 March 2022 are for Pacific Edge Limited (the ‘Company’) and its subsidiaries (collectively referred to as
the ‘Group’). The Group’s purpose is to research, develop and commercialise new diagnostic and prognostic tools
for the early detection and management of cancers.
Pacific Edge Limited is registered in New Zealand under the Companies Act 1993 and is a Financial Markets
Conduct (FMC) reporting entity under Part 7 of the Financial Markets Conduct Act 2013. The financial statements
of the Group have been prepared in accordance with the requirements of the Financial Markets Conduct Act 2013
and the NZX Listing Rules. The financial statements presented are those of the Group, consisting of the Parent
entity, Pacific Edge Limited and its subsidiaries. The Company is dual listed, with its primary listing of ordinary
shares quoted in New Zealand on the NZX Main Board, and a secondary listing in Australia as a Foreign Exempt
Entity on the ASX.
These financial statements have been approved for issue by the Board of Directors on the 25th May 2022.
Basis of Preparation
These financial statements of the Group have been prepared in accordance with Generally Accepted Accounting
Practice in New Zealand (NZ GAAP). The Group is a for-profit entity for the purposes of complying with NZ GAAP.
The financial statements comply with New Zealand equivalents to International Financial Reporting Standards (NZ
IFRS), other New Zealand accounting standards and authoritative notices that are applicable to entities that apply
NZ IFRS. The financial statements also comply with International Financial Reporting Standards.
The financial statements are presented in New Zealand Dollars, which is the Company’s functional currency and
Group’s presentation currency, and all values are rounded to the nearest thousand dollars ($000). The accounting
principles recognised as appropriate for the measurement and reporting of earnings, cash flows and financial
position on a historical cost basis have been used.
The Consolidated Statement of Comprehensive Income and Consolidated Statement of Cash Flows have been
prepared so that all components are stated net of GST. All items in the Consolidated Balance Sheet are stated net
of GST, with the exception of receivables and payables.
Management of Capital
The capital structure of the Group consists of equity raised by the issue of ordinary shares in the Company. The
Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going
concern in order to provide returns for shareholders, provide benefit for other stakeholders and to maintain an
optimal capital structure to support the development of its business. The Company meets these objectives through
closely managing revenue and expenditure, and where required issues new shares. As part of meeting these
objectives, the Company completed a Share Placement in September 2021 (issuing 59,259,259 shares at $1.35) and
a further Retail Offer in October 2021 (issuing 17,398,099 shares at $1.35 per share). Refer to Note 18 for further
details on the capital raising activity during FY22.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
8
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Basis of Consolidation
The following entities and the basis of their inclusion for consolidation in these Financial Statements are as follows:
Name of Subsidiary
Place of
Incorporation
(or registration)
& Operation
Principal Activity
Ownership Interests
& Voting Rights
31 March
2022
%
31 March
2021
%
Pacific Edge Diagnostics New Zealand
Limited
New Zealand
Commercial Sales and
Diagnostic Laboratory
Operation
100100
Pacific Edge (Australia) Pty LimitedAustralia
Biotechnology Research
& Development
100100
Pacific Edge Diagnostics USA LimitedUSA
Commercial Sales and
Diagnostic Laboratory
Operation
100100
Pacific Edge Diagnostics Singapore
Pte Limited
Singapore
Commercial Sales and
Biotechnology Research
& Development
100100
Pacific Edge Analytical Services
Limited
New ZealandDormant Company100100
The financial statements incorporate the assets, liabilities and results of all subsidiaries of Pacific Edge Limited as at 31
March 2022 and for the year then ended. All subsidiaries have the same balance date as the Company of 31 March.
Pacific Edge Limited consolidates all entities over which Pacific Edge Limited has control. Control is achieved when
the Group:
• Has power to direct the activities of the entity;
• Is exposed, or has rights, to variable returns from involvement with the entity; and
• Has the ability to use its power to affect its returns.
Subsidiaries which form part of the Group are consolidated from the date on which control is transferred to the
Group. They are de-consolidated from the date that control ceases.
The acquisition method of accounting is used to account for business combinations by the Group. The consideration
transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred and the
equity interest issued by the Group.
The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration
arrangement. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and
contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition
date. On an acquisition-by-acquisition basis, the Group recognises any non-controlling interest in the acquiree either
at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net assets. Inter-company
transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised
losses are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure
consistency with the policies adopted by the Group.
Critical Accounting Estimates and Assumptions
In preparing these financial statements, the Group made estimates and assumptions concerning the future.
These estimates and assumptions may differ from the subsequent actual results. Estimates and assumptions are
continually evaluated and are based on historical experience and other factors including expectations or future
events that are believed to be reasonable under the circumstances.
All significant accounting policies have been applied on a basis consistent with those used in the audited financial
statements of Pacific Edge Limited for the year ended 31 March 2021.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
9
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
2. NEW STANDARDS
New and Amended Standards Adopted by the Group
There are no new standards or interpretations material to the Group to be applied during the year.
New Standards and Interpretations Not Yet Adopted by the Group
Certain new accounting standards and interpretations have been published that are not mandatory for 31 March
2022 reporting periods and have not been early adopted by the Group. These standards are not expected to have
a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.
3. EARNINGS PER SHARE
(a) Basic
Basic earnings per share is calculated by dividing the profit (or loss) attributable to equity holders of the Company
by the weighted average number of ordinary shares on issue during the year excluding ordinary shares purchased
by the Company (Note 18).
GROUP
2022
($000)
2021
($000)
Loss attributable to equity holders of the Company (19,788) (14,223)
Weighted average number of ordinary shares on issue 767,924 714,031
Earnings per share (0.026) (0.020)
(b) Diluted
Diluted earnings per share is calculated by adjusting the weighted average number of shares outstanding to
assume conversion of all dilutive potential ordinary shares. The Group’s dilutive potential ordinary shares are in the
form of share options. As the Group made a loss during the current year and losses cannot be diluted, basic and
diluted earnings per share are the same.
4. LABORATORY THROUGHPUT AND COMMERCIAL TESTS –
NON-GAAP REPORTING
Laboratory Throughput is a key metric for the Group: Laboratory Throughput provides evidence of the usage
of Cxbladder products globally and the rates of adoption between different customer segments. The inclusion of
this non-GAAP reporting is considered helpful to readers of these accounts, as it allows readers to compare the
current period to prior periods and assess usage trends on a consistent basis. Total laboratory throughput includes
commercial tests, which are invoiced to customers (including tests for patients covered by the US government’s
medical program through the Centers for Medicare and Medicaid Services (CMS)), and tests which are not
considered to be commercial as these tests relate to Research Tests or other nonchargeable activities.
Commercial Test numbers are also a key metric for the Group: Commercial Tests are those tests for which the
Company is actively seeking reimbursement and cash receipts, and tests performed at no charge in order to gain
new customers. The inclusion of this non-GAAP reporting is considered helpful to readers of these accounts as it
allows readers to compare the current period to prior periods and assess trends on a consistent basis.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
10
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Laboratory Throughput and Commercial Tests per financial year are shown below.
FY22FY21
Total Laboratory Throughput (tests) 23,086 15,814
Change in Total Laboratory Throughput (%) 46%(6%)
Change in Throughput from previous year (tests) 7,272 (1,047)
Total Commercial Tests (tests) 19,196 12,976
Commercial Tests as a percentage of Total Laboratory
Throughput (%)
83%82%
Change in Commercial Tests from previous year (%)48%(5%)
5. REVENUE
Background information on US customers and the payment process
A physician orders a Cxbladder test when a patient presents to their clinic with symptoms that indicate the
possibility of bladder cancer. The most common and significant symptom is haematuria or blood in their urine.
A urine sample is collected from the patient and sent in the Cxbladder Urine Sampling System to the Group’s
laboratory in the US or in New Zealand. The Group receives and processes the urine sample and returns the results
of the test back to the ordering physician. The individual patient is the Group’s customer, however typically in the
US market, the patient’s insurer may pay the Group for some or all of the cost of the test.
When a physician orders a Cxbladder test, the Group has an obligation to perform the test and report the results to
the ordering physician irrespective of the patient’s insurance contract. A patient may have private insurance cover,
be covered by the US government’s medical program through CMS, self cover or have no insurance cover.
Once the Cxbladder test has been completed, all information required for insurance purposes is sent to the Group’s
billing and reimbursement agent to begin the process to collect reimbursement from any applicable insurance
company/ies for the Cxbladder test performed.
For patients with private insurance cover, the relevant patient and test order information will be sent to their
insurance provider. When the Group does not have an individual agreement with that insurance provider to pay
for Cxbladder tests (“out of network”), the insurance provider will assess that individual patient’s test for medical
necessity and the level of insurance cover (if any) available to cover the cost of the test. This process of assessment
can take many months to work through before the Group receives payments (if any) from the insurance company.
The Group does have agreements with some insurance providers but these currently cover a small proportion of
the Group’s customers.
For patients covered by CMS, invoices are sent to CMS. Prior to 3 July 2020, Pacific Edge was not included in the
Local Coverage Determination (LCD) and as a result, did not normally receive any amounts for tests performed
for patients covered by CMS. On 3 July 2020, Pacific Edge received notice of inclusion in the LCD, resulting in
the Company receiving reimbursement for Cxbladder Monitor and Detect tests performed after 1 July 2020 for
patients covered by the CMS across the US that are deemed medically necessary.
For uninsured patients, the Group has no certainty of when or if the patient will pay.
Rest of World Customers
Revenue from Rest of World customers is primarily from the District Health Boards (DHBs) in New Zealand. In all
Rest Of World locations, there is a clearly defined contract with the customer meeting the requirements of NZ IFRS
15. Pacific Edge Diagnostics New Zealand Limited has individual contracts with DHBs across New Zealand and
revenue is recognised as described on the following pages.
Critical Accounting Estimate
The application of NZ IFRS 15: Revenue from contracts with customers (NZ IFRS 15) requires the application of
significant judgement in determining whether the Group meets the five key criteria identified in NZ IFRS 15, which
must be met before revenue may be recognised as performance obligations are satisfied. For the Group this would
result in some revenue recognised in advance of the receipt of cash.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
11
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
The significant judgements adopted by the Group relate to :
- Determining if a contract with the customer exists;
- Identifying the rights of each party;
- Identifying the payment terms;
- Ensuring the contract has commercial substance; and
- Determining whether it is probable that the Group will collect the consideration to which it is entitled.
While there has been significant judgement applied to all five criteria, there are two criteria that have higher levels
of uncertainty, requiring increased levels of judgement. The significant judgements applied to determine the
Transaction Price and determining the probability of collecting consideration are detailed in the Accounting Policy
relating to Revenue from Cxbladder Tests.
ACCOUNTING POLICY
Revenue from Cxbladder tests
The Group performs Cxbladder tests when requested by a patient’s physician. At the point the test results are
returned to the physician, the Group has satisfied its performance obligation and has the right to issue an invoice.
The Group has determined a contract exists, and payment terms are identified, the contract has commercial
substance and the rights of each party have been identified.
On the 3 July 2020, Pacific Edge received notice of inclusion in the LCD, resulting in the Company receiving
reimbursement for Cxbladder Monitor and Detect tests performed after 1 July 2020 for patients covered by
the CMS across the US that are deemed medically necessary. Reimbursement for these tests is at the already
determined national CMS price for Cxbladder of US$760 per test.
Since Cxbladder’s inclusion in the LCD, based on historical data, the Group has been able to reliably estimate both
the probability and size of payment received from the CMS. The inclusion within LCD combined with the growing
support for the use of Cxbladder within the US has also allowed the Group to reliably estimate both the probability
and size of payment received from customers covered by Medicare Advantage policies provided by private
insurers.
Tests performed for patients covered by other private policies, or tests performed for those with no insurance
cover continue to be recognised as revenue when cash is received due to not being able to reliably estimate both
probability and size of payment received.
The Group have concluded that the contracts with the CMS and customers covered by Medicare Advantage
include variable consideration because the amounts paid by Medicare or the commercial health insurance
carriers that provide Medicare Advantage may be paid at less than our standard rates or not paid at all, with such
differences considered implicit price concessions. Variable consideration attributable to these price concessions is
measured at the expected value, and are determined by historical average collection rates by test type and payor
category taking into consideration the range of possible outcomes, the predictive value of our past experiences.
Such variable consideration is included in the transaction price only to the extent it is probable that a significant
reversal in the amount of cumulative revenue recognised will not occur.
A provision of $143,000 has been included to allow for tests that have been paid to the group and recognised
as revenue for the period to 31 March 2022, which are subsequently required to be refunded back to the payer
after the 31 March 2022 as a result of internal reviews undertaken by that payer. The estimation of the appropriate
allowance has been made by reviewing historical data of the Group.
As a result of the Significant Judgements applied, the Group have determined the criteria under NZ IFRS 15 which
allows revenue to be recognised in advance of the receipt of cash have been met, and the Group has recognised
revenue for tests which were performed from 1 April 2021 to 31 March 2022 for which payment has not been
received by 31 March 2022 for CMS and Medicare Advantage.
Rest of World revenue recognition from tests performed
There has been no change in accounting policy or estimates for Operating Revenue for the Rest of World.
The Group performs Cxbladder tests when requested by a patient’s physician in New Zealand, Australia and
Singapore. At the point the test results are returned to the physician, the Group has satisfied its performance
obligations have been met. At the end of the month an invoice is issued to the cutomer based on the number of
tests performed. Revenue is recognised when the test is returned.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
12
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
OTHER INCOME
Grant Income
Government Grants are not recognised until there is reasonable assurance that the Group will comply with the
conditions attached to them and that the grants will be received. Government Grants are recognised in Other
Income in the Consolidated Statement of Comprehensive Income, on a systematic basis over the periods in which
the Group recognises the related costs as expenses for which the grants are intended to compensate.
The Company receives grants from Callaghan Innovation for postgraduate internships and summer students.
New Zealand Trade and Enterprise awarded the Company an International Growth Fund grant, to support the
growth of the Group’s commercial and marketing operations in the US. The grant commenced on 17 August 2020
and runs until 16 August 2023. New Zealand Trade and Enterprise reimburses the Company for 50 percent of
eligible expenditure, up to a maximum of NZ$600,000, which was reached during the year ended 31 March 2022.
All conditions of the grants have been complied with.
Research Rebates and Tax Incentives
- New Zealand R&D Tax Incentive (RDTI)
The New Zealand RDTI is a 15% tax credit on the money invested in eligible research and development (R&D) that
has occurred in New Zealand. As the New Zealand companies are in a tax loss position, the Group is eligible for the
Tax Incentive to be refunded.
The RDTI is recognised at its fair value where there is a reasonable assurance that the credit will be received and
the Group will comply with all attached conditions.
All conditions of the New Zealand RDTI have been complied with. Payment will be received after submission of
each annual research and development tax claim.
- Australia Cxbladder Research Rebate
A Cxbladder research programme is administered by Pacific Edge Pty Limited and tax rebates are received as a
result of this programme.
The Cxbladder research rebate is recognised at its fair value where there is a reasonable assurance that the rebate
will be received and the Group will comply with all attached conditions.
All conditions of the research rebate have been complied with. Payment will be received after submission of each
annual research and development tax claim.
Covid-19 Support
During the previous year ended 31 March 2021, the Group received Covid-19 support in the countries in which it
operates. No support was received during the year ended 31 March 2022.
REVENUE AND OTHER INCOME
2022
($000)
2021
($000)
Cxbladder Sales
– US - Accrual Accounting 9,687 5,549
– US - Cash Accounting 953 1,339
– Total US Sales 10,640 6,888
– Rest Of World 805 813
Total Operating Revenue 11,445 7,701
Other Income
Grant Revenue 321 322
Research Rebates and Tax Incentives 1,370 952
Covid-19 Support 1,112
Total Other Income 1,691 2,386

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
13
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
PREVIOUSLY UNRECOGNISED REVENUE
Approximately 40% of Cxbladder tests performed by the Group in the US up to 30 June 2020 relate to patients
covered by the Centers for Medicare and Medicaid Services (CMS). The Group invoiced CMS for tests performed
for all patients with CMS coverage, however no revenue from these 22,634 tests has been recognised in the past.
In previous Financial Statements the Group reported that while no revenue has been received or recognised on
these 22,634 tests, the Group still noted the potential of future receipt as negotiations continued. Negotiations
have concluded and no further avenue is available for the Group to obtain reimbursement.
6. RESEARCH AND DEVELOPMENT COSTS
ACCOUNTING POLICY
Research is the original and planned investigation undertaken with the prospect of gaining new scientific
knowledge and understanding. This includes: direct and overhead expenses for diagnostic and prognostic
biomarker discovery and research; pre-clinical trials; and costs associated with clinical trial activities. All research
costs are expensed when incurred.
Development is the application of research findings to a plan or design for the production of new or substantially
improved processes or products prior to the commencement of commercial production.
When a project reaches the stage where it is probable that future expenditure can be recovered through the
process or products produced, expenditure that is directly attributed or reasonably allocated to that project is
recognised as a development asset within intangible assets. If the expenditure also benefits processes or products
for which it cannot be recovered, it will be expensed. The asset will be amortised from the date of commencement
of commercial production of the product to which it relates on a straight-line basis over the period of expected
benefit. Development assets are reviewed annually for any impairment in their carrying value.
GROUP
Notes
2022
($000)
2021
($000)
Research Expenses 5,135 4,584
Includes:
Employee Benefits8 2,664 2,423

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
14
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
7. GENERAL AND ADMINISTRATION EXPENSES
GROUP
Notes
2022
($000)
2021
($000)
Amortisation14 78 55
Auditors Remuneration: PricewaterhouseCoopers New Zealand*
- Group year end financial statements
- Half year review of financial statements
- Singapore Statutory financial statements
172
28
12
155
29
11
Auditors Remuneration: PricewaterhouseCoopers Singapore
- Statutory financial statements 12 12
Depreciation13 132 94
Depreciation on Right of Use Assets23 176 225
Directors Fees 413 278
Employee Benefits83,2162,507
Insurance 418 273
Interest on Lease Liabilities23 23 39
NZX, ASX and Registry Fees 901 121
Other Operating Expenses 2,175 1,611
7,756 5,410
* In addition to the Auditors Remuneration in the General and Administration Expenses, $NZ42,000 was paid to PwC Australia for
the review of the proforma financials related to the ASX Listing and Capital Raise and has been included in Issue Expenses within
Share Capital.
Note: Amounts displayed for Amortisation, Depreciation and Employee Benefits are only the General and Administration Expenses
component of the total expenses. Refer to relevant notes for full expense disclosure.
Other Operating Expenses
The major categories of expenditure which make up General and Administration Expenses, but are not disclosed
separately above are Information Technology costs, Compliance and Regulatory costs, Investor Relations costs,
Consultants and Contractors.

8. EMPLOYEE BENEFITS
GROUP
Notes
2022
($000)
2021
($000)
Represented by:
Employee Benefits:
Employee Benefits in Lab Operations 2,1451,879
Employee Benefits in Research62,6642,423
Employee Benefits in Sales and Marketing9,8486,616
Employee Benefits in General and Administration73,2162,507
Total Employee Benefits17,87313,425

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
15
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Employee Share Scheme
The Company has an Employee Share Scheme where ordinary shares in the Company may be issued to selected
employees to recognise performance or a significant contribution to the Company. These shares may be issued
in lieu of a cash bonus or in addition to the employee’s remuneration. The ordinary shares are issued directly to
the employee and the Company accounts for the cost of the shares. The shares are allocated to the employee on
the date that the Board approves the issue of the share capital. All employees who hold ordinary shares in the
Company must comply with the Company’s Share Trading Policy.
The issuance of ordinary shares to employees is treated as equity settled share-based payments. Equity-settled
share-based payments to employees are measured at the fair value of the equity instruments at the grant date
based on the market price at the time of issuance. The fair value of shares granted is recognised as an employee
expense in the Consolidated Statement of Comprehensive Income when the shares are issued. During the 2022
financial year, 123,000 (2021: 645,000) ordinary shares were issued to employees as part of the Employee Share
Scheme. The associated non-cash cost of these shares was $172,000 (2021: $284,000). Refer to Note 18 for further
details on the shares issued during the financial year.
Employee Share Option Scheme
The Board believes that the issue of share options provides an appropriate incentive for participating employees
to grow the total shareholder return of the Company. Share options are issued to selected employees to recognise
performance or contribution to the Company or as a long-term component of remuneration in accordance with the
Group’s remuneration policy.
The Company has two categories of Share Options which are outlined below:
Performance Options
Performance Options are issued to selected employees to recognise performance or a significant contribution to
the Company. Performance Options entitle the holder, on payment of the exercise price, to one ordinary share of
the Company. The exercise price of the granted options is determined using the fair value of the Company’s share
price at the time of the options being granted. Performance Options vest immediately and there is no service
requirement linked to the options or any other vesting conditions. The term in which options may be exercised, and
ultimately lapse if not exercised, is up to ten years.
Incentive Options
Incentive Options are issued to selected employees as a long-term component of remuneration in accordance
with the Group’s remuneration policy. Incentive Options entitle the holder, on payment of the exercise price, to one
ordinary share of the Company.
The exercise price of the granted options is determined using the fair value of the Company’s share price at the
time of the options being granted. Incentive Options vest over three years and there is a requirement to remain
as an employee of the Company in order for the options to vest. Tranches of options are exercisable over four to
ten years from the relevant vesting date. No options can be exercised later than the tenth anniversary of the final
vesting date.
ACCOUNTING POLICY
All options are accounted for as equity settled share based payments as the Group has no legal or constructive
obligation to repurchase or settle any awards in cash. The fair value of all options granted is recognised as an
expense in the Consolidated Statement of Comprehensive Income over their vesting period, with a corresponding
increase in the employee share option reserve.
The fair value is determined at the grant date of the options and expensed on a straight-line basis over the vesting
period, based on the Group’s estimate of equity instruments that will eventually vest, with a corresponding increase
in equity. At the end of each reporting period, the Group revisits its estimate of the number of equity instruments
expected to vest. The impact of the revision of the original estimates, if any, is recognised in the Consolidated
Statement of Comprehensive Income such that the cumulative expense reflects the revised estimate, with a
corresponding adjustment to the share based payments reserve.
During the year, there were 5,527,000 (2021: 3,636,000) share options exercised resulting in an increase in share
capital of $4,040,000 (2021: $2,636,000). Refer to note 18 for further details on the share options that were
exercised.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
16
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Movements in the number of options outstanding and their related weighted average exercise prices are as follows:
GROUP
20222021
Weighted average
exercise price
$
Options
#
Weighted average
exercise price
$
Options
#
Outstanding at 1 April0.42 15,952,289 0.42 18,137,598
Granted1.23 3,682,500 0.30 2,493,836
Forfeited 0.32 (246,076)0.23 (277,490)
Exercised*0.42 (5,527,394)0.41 (3,635,838)
Expired-- 0.80 (765,817)
Outstanding at 31 March0.60 13,861,319 0.39 15,952,289
Exercisable at 31 March0.27 9,908,171 0.31 12,765,384
* The weighted average share price at the date of options exercised during the year ended 31 March 2022 was NZ$1.35
(2021: NZ$0.92).
The Group used the Black-Scholes valuation model to determine the fair value of the equity instruments granted.
The Black-Scholes valuation model has been determined as the most appropriate method as it estimates the
theoretical value of derivatives taking into account the impact of time and other risk factors. The significant inputs
into the Black-Scholes valuation model were the market share price at grant date, the exercise price shown below,
the expected annualised volatility of 50-70%, a dividend yield of 0%, an expected option life of between one and
ten years and an annual risk-free interest rate of between 0.65% and 4.71%.
The volatility measured is the standard deviation of continuously compounded share returns and is based on a
statistical analysis of daily share prices in the past one to ten years.
Share options outstanding at the end of the reporting periods have the following expiry dates, vesting dates and
exercise prices:
Expiry MonthVesting Date
Exercise
Price
$
31 March 2022
Options
#
31 March 2021
Options
#
September 2021September 20170.80- 750,000
September 2024September 20140.6995,000180,000 *
April 2025April 20150.696,6666,666
July 2025July 20150.6912,49812,498
August 2025August 20150.724,1664,166
September 2025September 2015 0.72 14,99814,998
September 2025September 2015 0.69 15,00015,000
September 2025September 20150.5085,000190,000 *
November 2025November 20150.7283,33383,333
January 2026January 20160.7217,49817,498
April 2026April 20160.696,6676,667
July 2026July 20160.6912,50112,501
July 2026July 20160.508,3328,332
August 2026August 20160.722,8662,866
August 2026August 20160.508,3328,332
September 2026September 20160.7215,00115,001
September 2026September 20160.6915,00015,000

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
17
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Expiry MonthVesting Date
Exercise
Price
$
31 March 2022
Options
#
31 March 2021
Options
#
September 2026September 20160.5085,33385,333
November 2026November 20160.7283,33383,333
November 2026November 20160.608,3328,332
November 2026November 20160.4810,00030,000 *
December 2026December 20160.6010,83210,832
January 2027January 20170.7210,83410,834
February 2027February 20231.15600,000-
March 2027March 20170.604,1664,166
April 2027April 20170.696,6676,667
April 2027April 20170.6075,00075,000
July 2027July 20170.6910,012343,346
July 2027July 20170.504,1904,190
August 2027August 20170.508,3348,334
August 2027August 20170.484,1664,166
September 2027September 20170.7210,59410,594
September 2027September 20170.6915,00015,000
September 2027September 20170.5079,16879,168
September 2027September 20170.486,6666,666
November 2027November 20170.7283,33483,334
November 2027November 20170.608,3348,334
December 2027December 20170.603,7903,790
December 2027December 2017 0.51 4,1664,166
January 2028January 20180.727,4737,473
January 2028January 20180.5112,49812,498
February 2028February 20241.25600,000-
March 2028March 20180.604,1674,167
April 2028April 20180.6075,00075,000
May 2028May 20180.51836,6641,319,994
May 2028May 20180.286,6666,666
July 2028July 20180.502,6712,671
August 2028August 20180.504,3154,315
August 2028August 20180.483,9163,916
September 2028September 20180.50219219
September 2028September 20180.484,1284,128
October 2028October 20180.48-30,000
October 2028October 20180.288,3328,332
November 2028November 20180.606,8166,816
December 2028December 20180.514,1674,167
January 2029January 20190.516,4166,416
February 2029February 20190.286,6666,666

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
18
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Expiry MonthVesting Date
Exercise
Price
$
31 March 2022
Options
#
31 March 2021
Options
#
February 2029February 20251.25600,000-
March 2029March 20190.606868
April 2029April 20190.6075,00075,000
May 2029May 20190.51964,2471,414,249
May 2029May 20190.286,6676,667
June 2029June 20190.284,1664,166
July 2029July 2019 0.28 4,1664,166
August 2029August 20190.234,1664,166
October 2029October 20190.4840,00040,000
October 2029October 20190.288,3348,334
October 2029October 20190.234,1664,166
November 2029November 20190.238,3328,332
December 2029December 20190.512,7172,717
January 2030January 20200.513,7673,767
February 2030February 20200.286,6676,667
February 2030February 20261.25600,000-
May 2030May 20200.51906,3221,322,990
May 2030May 20200.285,3345,334
June 2030June 2020 0.28 2,4322,432
July 2030July 20200.284,1674,167
August 2030August 2020 0.23 437,4941,260,826
October 2030October 20200.288,3348,334
October 2030October 20200.234,1674,167
November 2030November 20200.238,3348,334
February 2031February 20210.286,6676,667
February 2031February 20271.25600,000-
June 2031June 20210.22388,888719,612
July 2031July 20210.284,1674,167
August 2031August 20210.23990,7462,754,172
October 2031October 20210.234,1674,167
November 2031November 20210.238,3348,334
December 2031December 20210.8335,000335,000
June 2032June 20220.22719,612719,612
August 2032August 20221.23210,825-
August 2032August 20220.232,617,3602,750,011
June 2033June 20230.22719,612719,612
August 2033August 20231.23210,837-
August 2034August 20241.23210,838-
13,861,31915,952,290
* Included within these tranches are 190,000 options (2021: 400,000 options) that vested immediately.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
19
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
9. CASH, CASH EQUIVALENTS AND SHORT TERM DEPOSITS
ACCOUNTING POLICY
Cash and cash equivalents includes cash in hand and deposits held on call with banks, and bank overdrafts. Term
deposits are also presented as cash equivalents if they have a maturity of three months or less from acquisition
date.
Short Term Deposits and Cash Equivalents include investments with ANZ, BNZ, Kiwibank and Westpac (2021: ANZ,
BNZ and Heartland), with periods ranging up to 365 days. Funds held on term deposit with ANZ, BNZ Westpac
and Kiwibank can be accessed with one month’s notice at the request of the authorised bank signatories of Pacific
Edge Limited.
GROUP
2022
($000)
2021
($000)
Cash and Cash Equivalents35,4124,129
Short Term Deposits70,00019,000
Total Cash, Cash Equivalents and Short Term Deposits105,41223,129
NZD84,51722,513
USD18,601578
AUD2,28425
EUR11
SGD912
Total Cash, Cash Equivalents and Short Term Deposits105,41223,129
INTEREST INCOME
ACCOUNTING POLICY
Interest income is recognised using the effective interest method.
Interest on the bank balances ranges from 0% to 1.89% (2021: 0% to 1.70%) per annum.
10. RECEIVABLES
ACCOUNTING POLICY
Receivables are initially measured at fair value and subsequently measured at amortised cost using the effective
interest rate method, less any provision for impairment. An allowance for impairment is made up of expected
credit losses based on the assessment of the trade receivables debt at the individual level for impairment, plus an
additional allowance on the remaining balance for potential credit losses not yet identified.
GROUP
2022
($000)
2021
($000)
Trade Receivables 1,633 1,016
Sundry Debtors 1,925 1,655
Accrued Interest 337 152
GST Refund Due / (Payable) 117 43
Total Receivables 4,012 2,866

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
20
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
There is no provision for impairment relating to the revenue from Cxbladder sales in New Zealand. All outstanding
sales are current and there are no expected credit losses on the amounts outstanding at balance date.
US Trade Receivables includes a provision for future refunds of $143,000.
Sundry Debtors include accruals for grants and rebates that have not yet been paid. These are expected to be paid
once the relevant claims have been submitted. The Company has met all conditions of the claims and there is no
indication that there is impairment of these balances.
Included in trade receivables are the below amounts which were past due but not impaired. These relate to a
number of customers for whom there is no history of default.
GROUP
2022
($000)
2021
($000)
3 to 6 Months 109 27
Total Overdue Trade Receivables 109 27
The foreign currency split of Receivables is:
GROUP
2022
($000)
2021
($000)
NZD 1,579 1,310
USD 1,550 935
AUD 883 621
Total Receivables 4,012 2,866
11. INVENTORY
ACCOUNTING POLICY
Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted average
formula.
GROUP
2022
($000)
2021
($000)
Laboratory Supplies 1,007 790
Total Inventory 1,007 790
The major items of Inventory are laboratory reagents, chemicals and Cxbladder urine sampling systems.
Laboratory supplies used during the year of $1,569,000 (2021: $1,261,000) are included within the Consolidated
Statement of Comprehensive Income in Laboratory Operations and Research.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
21
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
12. OTHER ASSETS
GROUP
2022
($000)
2021
($000)
Prepayments
1,014 398
Security Deposits
169 159
Total Other Assets
1,183 557
Prepayments are largely made up of insurance, industry conferences, subscriptions and travel not used. Security
deposits are paid to secure properties for lease in US and Singapore and to secure credit cards in the US.
13. PROPERTY, PLANT AND EQUIPMENT
ACCOUNTING POLICY
Property, Plant and Equipment are those assets held by the Group for the purpose of carrying on its business
activities on an ongoing basis. All Property, Plant and Equipment is stated at cost less subsequent accumulated
depreciation and any accumulated impairment losses. The cost of purchased assets includes the original purchase
consideration given to acquire the assets, and the value of other directly attributable costs that have been
incurred in bringing the assets to the location and condition necessary for their intended service. This includes the
laboratory equipment for the establishment of the laboratories.
Gains and losses on disposals are determined by comparing the net proceeds with the carrying amount and are
recognised within the Consolidated Statement of Comprehensive Income when they occur.

Depreciation
Depreciation of plant and equipment is based on writing off the assets over their useful lives, using the straight line
(SL) and diminishing value (DV) basis.
Main rates used are:
Plant and Laboratory Equipment 5% to 40% DV
Computer Equipment 5% to 67% DV
Leasehold Improvements 6% to 10% SL
Furniture and Fittings 5% to 25% DV
The assets’ useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
22
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022

Plant &
Laboratory
Equipment
($000)
Computer
Equipment
($000)
Leasehold
Improvements
($000)
Furniture
& Fittings
($000)
Total
($000)
Cost
Balance at 1 April 2020 2,385 764 331 348 3,828
Additions 195 46 29 - 270
Disposals (244) (246) (1) (22) (513)
Translation Difference (143) (52) (22) (27) (244)
Balance at 31 March 2021 2,193 512 337 299 3,341
Balance at 1 April 20212,193 512 337 299 3,341
Additions 511 232 213 33 989
Disposals (788) (362) (159) (7) (1,316)
Translation Difference 1 2 1 1 5
Balance at 31 March 2022 1,917 384 392 326 3,019
Accumulated Depreciation
Balance at 1 April 2020 2,073 677 149 277 3,176
Depreciation Expense 118 49 18 4 189
Disposals (237) (241) (1) (20) (499)
Translation Difference (130) (46) (11) (26)(213)
Balance at 31 March 2021 1,824 439 155 235 2,653
Balance at 1 April 2021 1,824 439 155 235 2,653
Depreciation Expense 150 89 14 10 263
Disposals (787) (355) (71) (91) (1,304)
Translation Difference 2 1 - - 3
Balance at 31 March 2022 1,189 174 98 154 1,615
Carrying Amounts
At 1 April 2020 312 87 182 71 652
At 31 March 2021 369 73 182 64 688
At 31 March 2022 728 210 294 172 1,404
14. INTANGIBLE ASSETS
ACCOUNTING POLICY
Intellectual Property
The costs of acquired Intellectual Property are recognised at cost. All Intellectual Property has a finite life.
The carrying value of Intellectual Property is reviewed for impairment, where indicators of impairment exist.
Amortisation is charged on a diminishing value basis over the estimated useful life of the intangible assets (1-20
years). The estimated useful life and amortisation method is reviewed at the end of each reporting period.
The following costs associated with Intellectual Property are expensed as incurred during the research phases of
a project and are only capitalised when incurred as part of the development phase of a process or product within
development assets: Internal Intellectual Property costs including the costs of patents and patent application.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
23
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Software Development Costs
Costs associated with the development of software are held at cost. Amortisation is charged on a diminishing value
basis over the estimated useful life of the intangible assets (2-10 years). The estimated useful life and amortisation
method is reviewed at the end of each reporting period.
Cxblader Development Costs
Costs associated with the development of Cxbladder products are held at cost. Amortisation is charged on a
diminishing value basis over the estimated useful life of the intangible assets (20 years). The estimated useful life
and amortisation method is reviewed at the end of each reporting period.
Software
Development
Costs
($000)
Patents
($000)
Cxbladder
Development
Costs
($000)
Total
($000)
Cost
Balance at 1 April 2020 887 347 33 1,267
Additions 40 68 - 108
Foreign Translation Difference (6)-- (6)
Balance at 31 March 2021 921 415 33 1,369
Balance at 1 April 2021 921 415 33 1,369
Additions 278 135 - 413
Foreign Translation Difference----
Balance at 31 March 2022 1,199 550 33 1,782
Accumulated Amortisation
Balance at 1 April 2020 799 273 16 1,088
Amortisation Expense 53 55 2 110
Foreign Translation Difference (6)-- (6)
Balance at 31 March 2021 846 328 18 1,192
Balance at 1 April 2021 846 328 18 1,192
Amortisation Expense 87 67 2 156
Foreign Translation Difference----
Balance at 31 March 2022 933 395 20 1,348
Carrying Amounts
At 31 March 2020 88 74 17 179
At 31 March 2021 75 87 15 177
At 31 March 2022 266 155 13 434
15. SEGMENT INFORMATION
ACCOUNTING POLICY
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing
performance of the operating segments, has been identified as the Chief Executive Officer who makes strategic
decisions.
There are two operating segments at balance date:
1. Commercial: The sales, marketing, laboratory and support operations to run the commercial businesses worldwide.
2. Research: The research and development of diagnostic and prognostic products for human cancer.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
24
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
The reportable operating segment Commercial derives its revenue primarily from sales of Cxbladder tests and
the reportable operating segment Research derives its revenue primarily from grant income. The Chief Executive
Officer assesses the performance of the operating segments based on their net result for the period.
Segment income, expenses and profitability are presented on a gross basis excluding inter-segment eliminations
to best represent the performance of each segment operating as independent business units. The segment
information provided to the Chief Executive Officer for the reportable segment described above, for the year
ended 31 March 2022, is shown below.
2022
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
($000)
Income
Operating Revenue - External 11,445 -- 11,445
- Internal----
Other Income 437 2,187 (933) 1,691
Interest Income 2 547 - 549
Foreign Exchange Gain- 193 - 193
Total Income 11,884 2,927 (933) 13,878
Expenses
Expenses 20,378 12,737 (933) 32,182
Depreciation & Amortisation 977 507 - 1,484
Total Operating Expenses 21,355 13,244 (933) 33,666
Loss Before Tax (9,471) (10,317)- (19,788)
Income Tax Expense----
Loss After Tax (9,471) (10,317)- (19,788)
Net Cash Flow to Operating Activities (8,620) (8,932)- (17,552)
2021
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
($000)
Income
Operating Revenue - External 7,701 - - 7,701
- Internal-- - -
Other Income 1,224 2,130 (968) 2,386
Interest Income 1 350 - 351
Foreign Exchange Gain 3 (2) - 1
Total Income 8,929 2,478 (968) 10,439
Expenses
Expenses 14,529 9,730 (968) 23,291
Depreciation and Amortisation 934 437 - 1,371
Total Operating Expenses 15,463 10,167 (968) 24,662
Loss Before Tax (6,534) (7,689) - (14,223)
Income Tax Expense-- - -
Loss After Tax (6,534) (7,689) - (14,223)
Net Cash Flow to Operating Activities (6,438) (7,132) - (13,570)

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
25
Eliminations
These are the intercompany transactions between the subsidiaries and the Parent. These are eliminated on
consolidation of Group results. The Research segment of the business utilise consumables and other components
that are purchased by the Commercial segments of the business, with the costs of these components allocated to
the Research segment, and the Commercial segment recognising the revenue from the sale.
Segment Assets and Liabilities Information
2022
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 6,031 109,251 115,282
Total Liabilities 4,571 2,335 6,906

2021
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 5,477 25,707 31,184
Total Liabilities 4,529 1,546 6,075
Additions to Non Current Assets for the period include:
Commercial
($000)
Research
($000)
Total
($000)
Property, Plant and Equipment 823 166 989
Right of Use Assets 148 - 148
Intangible Assets 279 134 413
Total Additions to Non Current Assets 1,250 300 1,550
The amounts provided to the Chief Executive Officer with respect to total assets and total liabilities are measured
in a manner consistent with that of the financial statements. These assets and liabilities are allocated based on the
operation of the segment and the physical location of the asset.
There are no unallocated assets or liabilities.
Geographic Split of Revenue and Non-Current Assets
The Group generates most of the operating revenue from Commercial tests from the US and New Zealand, and
also receives Grant revenue from Australia and New Zealand. Rest of World consists of Revenue from Australia and
Singapore.
2022
($000)
2021
($000)
Operating and Grant Revenue
US 10,640 7,677
New Zealand 1,729 2,133
Rest of World 767 277
Total Operating and Grant Revenue 13,136 10,087
2022
($000)
2021
($000)
Non-Current Assets
US 1,611 2,201
New Zealand 2,057 1,618
Rest of World- 23
Total Non-Current Assets 3,668 3,842
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
26
16. INCOME TAX
ACCOUNTING POLICY
The tax expense for the period comprises current and deferred tax. Tax is recognised in the Consolidated
Statement of Comprehensive Income, except to the extent that it relates to items recognised in other
comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income
or directly in equity, respectively.
The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the
balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income.
Management periodically evaluates positions taken in tax returns with respect to situations in which applicable
tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts
expected to be paid to the tax authorities.
Deferred income tax is provided in full, using the liability method, on temporary differences arising between the
tax bases of assets and liabilities and their carrying amounts in the financial statements in accordance with NZ
IAS 12. Deferred income tax assets are recognised to the extent that it is probable that future taxable profit will be
available against which the temporary differences can be utilised.
Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by
the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the
deferred income tax liability is settled.
The Company and Group has incurred an operating loss for the 2022 financial year and no income tax is
payable.
GROUP
2022
($000)
2021
($000)
Income Tax recognised in the profit or loss:
Current tax expense--
Deferred Tax in respect of the current year (4,258) (6,291)
Adjustments to deferred tax in respect to prior years94 512
Deferred tax assets not recognised4,164 5,779
Income tax expense--

The prima facie income tax on pre-tax accounting profit
from operations reconciles to:
Accounting loss before income tax (19,788) (14,223)
At the statutory income tax rate of 28% (5,541) (3,982)
Non-deductible expenditure 626 (2,760)
Difference in US, Singapore and Australian income tax rates 657 451
Prior period adjustment94 512
Deferred tax assets not recognised4,164 5,779
Income tax expense reported in Consolidated Statement
of Comprehensive Income
--
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
27
Tax Losses
The group has losses to carry forward of approximately $112,330,000 (2021: $94,400,000) with a potential tax
benefit of $25,694,000 (2021: $21,500,000). The tax losses are split between the following jurisdictions:
Tax Losses
($000)
Tax Effect
($000)Rate
New Zealand 29,200 8,200 28%
Australia 1,200 400 30%
Singapore 1,500 200 17%
United States 80,300 16,900 21%
Tax losses are available to be carried forward and offset against future taxable income subject to the various
conditions required by income tax legislation being complied with.
Deferred Research and Development Tax Expenditure:
The Group also has deferred research and development tax expenditure of $45,846,000 (2021: $42,200,000) to
carry forward and claim for income tax purposes in New Zealand in the future. This has a tax effect of $12,889,000
(2021: $11,900,000). The deferred research and development tax expenditure can either be carried forward and
offset against future income arising from the research and development, or subject to meeting the shareholder
continuity requirements can be offset against future other taxable income.
Deferred Tax Assets:
The Group does not recognise a deferred tax asset in the Consolidated Balance Sheet.
Imputation Credit Account
The Group has imputation credits of Nil (2021: Nil).
17. PAYABLES AND ACCRUALS
ACCOUNTING POLICY
Trade and Other Payables Due Within One Year
Trade payables are recognised at the value of the invoice received from a supplier. The carrying value of trade
payables is considered to approximate fair value as amounts are unsecured and are usually paid by the 30th of the
month following recognition.
GROUP
2022
($000)
2021
($000)
Trade Creditors 1,906 818
Accrued Expenses 659 411
Employee Entitlements (refer below) 2,418 1,968
Total Payables and Accruals 4,983 3,197
Payables and accruals are non-interest bearing and are normally settled on 30 day terms, therefore their carrying
value approximates their fair value.
The foreign currency split for Payables and Accruals is:
GROUP
2022
($000)
2021
($000)
NZD 2,161 1,025
AUD 131 126
USD 2,656 2,013
SGD 35 33
4,983 3,197
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
28
Employee Entitlements
Employee entitlements are measured at values based on accrued entitlements at current rates of pay. These include
salaries and wages accrued up to balance date and annual leave earned to, but not yet taken at balance date.
GROUP
2022
($000)
2021
($000)
Income Tax 214 361
Holiday Pay 360 261
Accrued Wages 1,844 1,346
Total Employee Entitlements 2,418 1,968
18. SHARE CAPITAL
ACCOUNTING POLICY
Ordinary shares are described as equity.
Issue expenses, including commission paid, relating to the issue of ordinary share capital, have been written off
against the issued share price received and recorded in the Consolidated Statement of Changes in Equity.
Equity-settled share-based payments to employees and others providing services are measured at the fair value
of the equity instruments at the grant date. Details regarding the determination of the fair value of equity-settled
share based transactions are set out in Note 8.
GROUP
2022
($000)
2021
($000)
Ordinary Shares Authorised 294,139 190,305
Total Share Capital 294,139 190,305
All fully paid shares in the Group are Authorised and have equal voting rights and equal rights to dividends. All
Ordinary Shares are fully paid and have no par value.
Share Capital Group
2022 Shares
(000)
2022
($000)
2021 Shares
(000)
2021
($000)
Opening Balance 727,779 190,305 689,652 165,423
Issue of Ordinary Shares
- Placement
1
76,657 103,487 33,846 22,000
Issue of Ordinary Shares
- Exercise of share options
2
5,528 4,040
3,636
2,636
Issue of Ordinary Shares
- Employee Remuneration
3
123 172 645 284
Less: Issue Expenses
- (3,865)- (38)
Movement 82,308 103,834 38,127 24,882
Closing Balance 810,087 294,139 727,779 190,305
1) During the period 76,657,358 shares were issued under placements at $1.35 per share. (2021: 33,846,154 at $0.65)
2) During the period 5,527,391 share options were exercised at an average price of $0.42 per share (2021: 3,635,835 at an average
price of $0.41)
3) During the period 123,086 shares were issued as part of employees remuneration in lieu of cash payments at an average price
of $1.40 per share. (2021: 645,182 at $0.44)
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
29
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
19. FOREIGN CURRENCY
ACCOUNTING POLICIES
Foreign Currency Transactions
The individual financial statements of the Group are presented in the currency of the primary economic
environment in which the entity operates (its functional currency). For the purpose of the Group financial
statements, the results and financial position of the Group entity are expressed in New Zealand dollars (‘NZ$’),
which is the functional currency of the Parent and the presentation currency for the Group financial statements.
In preparing the financial statements of the individual entities, transactions in currencies other than the entity’s
functional currency (foreign currencies) are recorded at the rates of exchange prevailing at the dates of the
transactions. At the end of each reporting period, monetary items denominated in foreign currencies are
retranslated at the rates prevailing at the end of the reporting period. Non monetary items denominated in foreign
currencies are translated at the rates prevailing on the date the transaction occurs.
Exchange differences are recognised in the Consolidated Statement of Comprehensive Income in the period in
which they arise.
Foreign Operations
For the purpose of presenting the Group financial statements, the assets and liabilities of the Group’s foreign
operations are expressed in New Zealand dollars using exchange rates prevailing at the end of the reporting
period. Income and expense items are translated at the average exchange rates for the period, unless exchange
rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transactions
are used. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated as
a separate component of equity in the Group’s foreign currency translation reserve. Such exchange differences
are reclassified from equity to profit or loss (as a reclassification adjustment) in the period in which the foreign
operation is disposed of.
Foreign Currency Translation Reserve
Exchange differences relating to the translation from the functional currencies of the Group’s foreign subsidiaries into
New Zealand dollars are brought to account by entries made directly to the Foreign Currency Translation Reserve.
20. RECONCILIATION OF CASH FLOWS TO OPERATING ACTIVITIES WITH NET LOSS
GROUP
2022
($000)
2021
$000
Net Loss for the Period (19,788) (14,223)
Add Non Cash Items:
Depreciation 263 189
Loss on disposal of Property, Plant and Equipment 11 13
Amortisation 156 110
Employee Share Options 839 1,035
Employee Bonuses paid in shares in lieu of cash 172 284
Depreciation on Right of Use Assets1,064 1,073
Interest on finance leases shown in lease repayments 126 103
Total Non Cash Items 2,631 2,807
Add Movements in Other Working Capital items:
Increase in Receivables and Other Assets (1,772) (2,088)
Increase (Decrease) in Inventory (217) 6
Increase (Decrease) in Payables and Accruals 1,786 (71)
Effect of exchange rates on net cash (192) (1)
Total Movement in Other Working Capital (395) (2,154)
Net Cash Flows to Operating Activities (17,552) (13,570)

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
30
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
21. FINANCIAL INSTRUMENTS
ACCOUNTING POLICY
Foreign Currency Transactions
Financial instruments include cash and cash equivalents, short term deposits, receivables, security deposits, finance
lease liabilities and trade creditors. The particular recognition methods adopted are disclosed in the individual
policy statements associated with each item.
Managing Financial Risk
The Group’s activities expose it to the financial risks of changes in interest rate risk, credit risk, liquidity risk and
foreign currency risk.
Management is of the opinion that the Company and Group’s exposure to market risk during the period and at
balance date is defined as:
Risk FactorDescription
(i) Currency riskFinancial assets and financial liabilities are denominated in NZD, USD, AUD, SGD and
EUR currencies
(ii) Interest rate risk Exposure to changes in Bank interest rates resulting in cashflow interest rate risk
(iii) Credit RiskRisk of financial loss in counterparty fails to meet contractual obligations
(iv) Liquidity RiskRisk the Group may not be able to meet its commitments as they fall due
(v) Other price riskNot applicable as no securities are bought, sold or traded
(i) Foreign Currency Risk
The Group faces the risk of movements in foreign currency exchange rates in relation to the New Zealand dollar.
The Group has significant operations in United States Dollars and less significant operations in Australian dollars,
Euros and Singapore dollars. As a result of this, the financial performance and financial position are impacted by
movements in exchange rates.
The Group manages foreign currency risk by purchasing overseas goods only when necessary. It will also purchase
foreign currency to fund overseas operations based on cash flow forecasts where it can maximise value. There are
no formal foreign currency hedges entered into.
A 10% increase or decrease in foreign currency against the NZD will reduce/increase the loss reported by
approximately $167,000 (2021: $130,000) and increase/reduce equity by the same amount.
(ii) Interest Rate Risk
The Group’s interest rate risk arises from its cash and equivalents, and short term deposits. Cash and equivalents
comprise cash on hand and deposits at call with banks. Short term deposits comprise of term deposits placed with
New Zealand banks on fixed rates for different periods of time.
Management regularly review its banking arrangements to ensure it achieves the best returns on its funds while
maintaining access to necessary liquidity levels to service the Group’s day-to-day activities. The mixture of bank
deposits at floating interest rates and short term deposits at different rates over various periods of time mitigate
the risk of interest rates being received at less than market rates. The Group does not enter into interest rate
hedges.
A 1% increase or decrease in bank deposit interest rates will reduce/increase the loss reported by approximately
$1,041,000 and increase/reduce equity by the same amount (2021: $219,000).
(iii) Credit Risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to
meet its contractual obligations.
The Group incurs credit risk from:
a) Cash and short term deposits;
b) Receivables in the normal course of its business; and
c) Other assets.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
31
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
The Group has no significant concentration of credit risk other than bank deposits with 26.1% at Westpac, 25.4%
at BNZ, 22.3% at ANZ, 17.4% at Kiwibank and 0.4% at Wells Fargo. The Group’s cash and short term deposits are
placed with high credit quality financial institutions including major banks who have at least a A+ credit rating
Regular monitoring of receivables is undertaken to ensure that the credit exposure remains within the Group’s
normal terms of trade. These receivables balances mainly relate to New Zealand customers, US customers, and the
Australian Government. Refer to note 10 for further details on expected credit losses for receivables.
The Group continues to invoice for every billable test completed in the US, and the billing and reimbursement
process continues to maximise the cash that is received by the Group. The Group has included an accrual for tests
performed from 1 April 2021 to 31 March 2022 for which payment has not been received by 31 March 2022.
Regular monitoring of other assets is undertaken to ensure that the credit exposure is limited. This is firstly done
by determining the credit risk before making security deposits on leased properties and ensuring suppliers are not
paid in advance where there is uncertainty in relation to their credit worthiness.
The carrying values of financial assets represent the maximum exposure to credit risk as represented below:
GROUP
Notes
2022
($000)
2021
($000)
Cash and Cash Equivalents935,4124,129
Short Term Deposits970,00019,000
Trade and Other Receivables (excludes GST)103,8952,824
Other Assets (excludes prepayments)12 169 159
109,47626,112
(iv) Liquidity Risk
Liquidity risk is the risk that the Group may encounter difficulty in raising funds at short notice to meet its
commitments as they fall due. Management maintains sufficient cash balances and uses cash flow forecasts to
determine future cash flow requirements. The Group does not have any external loans but does have four finance
leases.
Payables and Accruals totaling $4,983,000 are due within 3 months of balance date (2021: $3,197,000).
Fair Values
In the opinion of the Directors, the carrying amount of financial assets and financial liabilities approximate their fair
values at balance date.
22. RELATED PARTIES
A shareholder, the University of Otago, provided services, including rental space and car parking, to the Group to
the value of $361,000 (2021: $340,000). The Group has commitments totaling $269,000 (2021: $267,000) with the
University of Otago in the next financial year.
Key Management Compensation
Key management personnel comprise of Directors and the Chief Executive Officer (current and retired) of Pacific
Edge Limited, and the Chief Executive Officer and Executive Chairman of Pacific Edge Diagnostics USA Limited.
Refer to Note 8 for details of the Incentive Plan that includes key management remuneration.
GROUP
2022
($000)
2021
($000)
Salaries and Other Short Term Employee Benefits2,2071,861
Consulting Fees105-
Share Options Benefits 445 313
Total Employee Entitlements2,7572,174

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
32
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Directors’ Fees
The current total Directors’ fee pool for non-executive Directors of Pacific Edge Limited, approved by the
shareholders at the Annual Shareholders Meeting on the 29th July 2021 is $465,000 per annum. During the year
ended 31 March 2022, Tony Barclay was appointed to the board (21st March 2022) and David Darling ceased on
the board (17th January 2022). The total amount of fees paid to Directors for the year ended 31 March 2022 was
$413,000.
The table below sets out the total fees approved for non-executive Directors of Pacific Edge Limited for the year
ended 31 March 2022 based on the positions held:
PositionQuantity
2022
Total Fees
Approved
2022
Quantity
2021
Total Fees
Approved
2021
Chair1$115,0001$80,000
Deputy Chair 1$70,0001$50,000
Non-executive Directors4$240,0002$88,000
Chair Audit & Risk Committee1$10,0001$5,000
Special Governance Allocation$30,000-
US-based non-executive Director-1$79,000
Total Fee Pool$465,000$302,000
23. FINANCE AND OPERATING LEASE COMMITMENTS
ACCOUNTING POLICY
The group leases various properties and equipment. Rental contracts vary depending on the type of asset
being leased. Lease terms are negotiated on an individual basis and contain a wide range of different terms and
conditions. The lease agreements do not impose any covenants, but leased assets may not be used as security for
borrowing purposes.
Contracts may contain both lease and non-lease components. The Group allocates the consideration in the
contract to the lease and non-lease components based on their relative stand-alone prices.
Leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is
available for use by the Group. Each lease payment is allocated between the liability and finance cost. The finance
cost is charged to the Consolidated Statement of Comprehensive Income over the lease period to produce a
constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is
depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis.
(i) Measurement basis
Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the
net present value of the following lease payments:
• Fixed payments (including in-substance fixed payments), less any lease incentives receivable;
• Variable lease payments that are based on an index or a rate;
• Amounts expected to be payable by the lessee under residual value guarantees;
• The exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and
• Payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.
Lease payments to be made under reasonably certain extension options are also included in the measurement of
the liability.
The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily
determined, which is generally the case for leases in the group, the lessee’s incremental borrowing rate is used. The
incremental borrowing rate is the rate that the individual lessee would have to pay to borrow the funds necessary
to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms,
security and conditions.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
33
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
To determine the incremental borrowing rate, the Group:
• Where possible, uses recent third-party financing received by the individual lessee as a starting point, adjusted to
reflect changes in financing conditions since third-party financing was received;
• Uses a build-up approach that starts with a risk-free interest rate adjusted for credit risk for leases held by Pacific
Edge Limited, which does not have recent third-party financing; and
• Makes adjustments specific to the lease, e.g. term, country, currency and security.
The Group is exposed to potential future increases in variable lease payments based on an index or rate, which are
not included in the lease liability until they take effect. When adjustments to lease payments based on an index or
rate take effect, the lease liability is reassessed and adjusted against the right-of-use asset.
Lease payments are allocated between principal and finance cost. The finance cost is charged to the Consolidated
Statement of Comprehensive Income over the lease period to produce a constant periodic rate of interest on the
remaining balance of the liability for each period. The 2021 comparative for lease repayments in the Consolidated
Statement of Cashflows has been split between principal and interest to be comparable with the current year
reporting.
Right-of-use assets are measured at cost comprising the following:
• The amount of the initial measurement of lease liability;
• Any lease payments made at or before the commencement date;
• Any initial direct costs; and
• Restoration costs.
Right-of-Use assets are generally depreciated over the shorter of the asset’s useful life and the lease term on
a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the Right-of-Use asset is
depreciated over the underlying asset’s useful life.
Payments associated with short-term leases and leases of low-value assets are recognised on a straight-line basis
as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less. Low-value assets
include IT equipment and small items of office furniture.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
34
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
Right of Use Assets
GROUP
2022
($000)
2021
($000)
Cost
Opening Balance 3,914 2,518
Additions 179 2,588
Removals (Leases Completed) (366) (1,227)
Foreign Currency Translation(122) 35
Closing Balance3,605 3,914

Accumulated Depreciation
Opening Balance 937 937
Depreciation1,064 1,083
Reversal of Accumulated Depreciation (Leases Completed)(153) (1,204)
Foreign Currency Translation(73) 121
Closing Balance1,775937
Net Right of Use Assets Balance1,8302,977
Right of Use Assets Net Book Value
Buildings 1,792 2,624
Computer Equipment 38 62
Plant and Equipment- 291
1,830 2,977
Depreciation
Buildings1,018 966
Computer Equipment 24 18
Plant and Equipment 22 99
1,064 1,083
Expenses relating to Short Term and Low Value Leases 74 24
Total Cash Outflow relating to Leases 1,273 1,250

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
35
Notes to the Consolidated Financial Statements
For the year ended 31 March 2022
GROUP
Lease Liability
2022
($000)
2021
($000)
Opening Balance 2,878 1,554
Additions 148 2,587
Lease Terminated - Liability Reversed- (26)
Lease Repayments (1,230) (1,262)
Interest Charged 126 107
Foreign Currency Translation 1 (82)
Closing Balance 1,923 2,878
Split by:
Current Liability 1,072 1,098
Non-Current Liability 851 1,780
1,923 2,878
The maturity of the Lease Liabilities is as follows:
Less than one year 1,072 1,103
One to two years 671 999
Two to three years 51 595
More than three years 129 181
1,923 2,878
24. OTHER COMMITMENTS AND CONTINGENT LIABILITIES
a) Contingent Liabilities
There were no known contingent liabilities at 31 March 2022 (March 2021: Nil). The Group has not granted any
securities in respect of liabilities payable by any other party whatsoever.
b) Capital Commitments
There are no capital commitments at 31 March 2022 (March 2021: Nil).
25. COVID-19
Covid-19 continues to have had an impact on the throughput, revenue and expenses of the Group for the year
ended 31 March 2022. 
In the markets the Group operates in, measures have been employed by Governments in an attempt to limit the
spread of the virus. This has restricted the ability for people to visit clinics and have tests performed. 
While throughput quantities for the group for the year ended 31 March 2022 are up 46% on the prior year, the
restricted access to clinics has offset some of the increase expected from the increased Sales and Marketing
expenditure (up 55% on the prior year).
The benefits of the increased investment in Sales and Marketing are expected to be realised by the Group in the
next 12 months as Covid-19 restrictions are relaxed and/or removed.
The Group has Cash, Cash Equivalents and Short Term Deposits of $105,412,000, which provides confidence in the
ability of the Group to manage any on-going impacts caused by Covid-19.
26. SUBSEQUENT EVENTS
There are no subsequent events.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
36


PricewaterhouseCoopers, Westpac Building, 106 George Street, PO Box 5848, Dunedin 9058, New Zealand
T: +64 3 470 3600, pwc.co.nz


Independent auditor’s report
To the shareholders of Pacific Edge Limited
Our opinion
In our opinion, the accompanying consolidated financial statements of Pacific Edge Limited (the
Company), including its subsidiaries (the Group), present fairly, in all material respects, the financial
position of the Group as at 31 March 2022, its financial performance and its cash flows for the year
then ended in accordance with New Zealand Equivalents to International Financial Reporting
Standards (NZ IFRS) and International Financial Reporting Standards (IFRS).
What we have audited
The Group's consolidated financial statements comprise:
● the consolidated balance sheet as at 31 March 2022;
● the consolidated statement of comprehensive income for the year then ended;
● the consolidated statement of changes in equity for the year then ended;
● the consolidated statement of cash flows for the year then ended; and
● the notes to the consolidated financial statements, which include significant accounting policies
and other explanatory information.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (New Zealand) (ISAs
(NZ)) and International Standards on Auditing (ISAs). Our responsibilities under those standards are
further described in the Auditor’s responsibilities for the audit of the consolidated financial statements
section of our report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.
Independence
We are independent of the Group in accordance with Professional and Ethical Standard 1 International
Code of Ethics for Assurance Practitioners (including International Independence Standards) (New
Zealand) (PES 1) issued by the New Zealand Auditing and Assurance Standards Board and the
Int ernational Code of Ethics for Professional Accountants (including International Independence
Standards) issued by the International Ethics Standards Board for Accountants (IESBA Code), and we
have fulfilled our other ethical responsibilities in accordance with these requirements.
Our firm carries out other services for the Group in the areas of half year review procedures and with
providing other assurance services. The provision of these other services has not impaired our
independence as auditor of the Group.
Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in
our audit of the consolidated financial statements of the current year. These matters were addressed
in the context of our audit of the consolidated financial statements as a whole, and in forming our
opinion thereon, and we do not provide a separate opinion on these matters.



PricewaterhouseCoopers, Westpac Building, 106 George Street, PO Box 5848, Dunedin 9058, New Zealand
T: +64 3 470 3600, pwc.co.nz


Independent auditor’s report
To the shareholders of Pacific Edge Limited
Our opinion
In our opinion, the accompanying consolidated financial statements of Pacific Edge Limited (the
Company), including its subsidiaries (the Group), present fairly, in all material respects, the financial
position of the Group as at 31 March 2022, its financial performance and its cash flows for the year
then ended in accordance with New Zealand Equivalents to International Financial Reporting
Standards (NZ IFRS) and International Financial Reporting Standards (IFRS).
What we have audited
The Group's consolidated financial statements comprise:
● the consolidated balance sheet as at 31 March 2022;
● the consolidated statement of comprehensive income for the year then ended;
● the consolidated statement of changes in equity for the year then ended;
● the consolidated statement of cash flows for the year then ended; and
● the notes to the consolidated financial statements, which include significant accounting policies
and other explanatory information.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (New Zealand) (ISAs
(NZ)) and International Standards on Auditing (ISAs). Our responsibilities under those standards are
further described in the Auditor’s responsibilities for the audit of the consolidated financial statements
section of our report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.
Independence
We are independent of the Group in accordance with Professional and Ethical Standard 1 International
Code of Ethics for Assurance Practitioners (including International Independence Standards) (New
Zealand) (PES 1) issued by the New Zealand Auditing and Assurance Standards Board and the
Int ernational Code of Ethics for Professional Accountants (including International Independence
Standards) issued by the International Ethics Standards Board for Accountants (IESBA Code), and we
have fulfilled our other ethical responsibilities in accordance with these requirements.
Our firm carries out other services for the Group in the areas of half year review procedures and with
providing other assurance services. The provision of these other services has not impaired our
independence as auditor of the Group.
Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in
our audit of the consolidated financial statements of the current year. These matters were addressed
in the context of our audit of the consolidated financial statements as a whole, and in forming our
opinion thereon, and we do not provide a separate opinion on these matters.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
37




PwC


Description of the key audit matter How our audit addressed the key audit matter
Determining the timing of revenue
recognition for US revenue
As disclosed in Note 5 of the consolidated
financial statements, the timing of revenue
recognition for US based revenue varies by
revenue stream between completion of the
Cxbladder test and receipt of cash.
The Company has two material United States
(US) revenue streams:
1. Coverage via Centers for Medicare and
Medicaid Services (CMS), and
2. Private Insurance.
In July 2020, the Company received Local
Coverage Determination (“LCD”) for CMS. This
determination created a set price for the
Company’s tests of US$760 per test from July
2020. This established a clear transaction price
for the tests. This transaction price, along with a
history of payment, satisfies the NZ IFRS
requirements for revenue recognition.
Accordingly, in the current year US derived
revenue for tests performed for CMS and
Medicare Advantage has been recognised in
advance of cash being received. Revenue for
these customers is recognised when the tests
are performed.
All other US derived revenue is accounted for
on a cash receipts basis as disclosed in Note 5.



Our audit procedures included the following:
We obtained an understanding of management's processes
and controls for the CMS and Private Insurance US revenue
streams, including the relevant controls at the external billing
reimbursement service organisation. We obtained the SOC1
System and Organisation Controls Report for the external
billing reimbursement service organisation, and evaluated
the evidence provided over the design and operating
effectiveness of the relevant controls.
We evaluated management's determination of whether a
contract with customers existed by:
● Assessing the data supporting revenue recognition for
CMS and Medicare Advantage to confirm that the
transaction price can be determined and collectability is
probable;
● Assessing the data supporting revenue recognition for
private insurance to confirm that the transaction price
and collectability is only probable when cash is received;
● Performing subsequent receipt testing to validate the
probability of collection of the year end receivable and
performing look back procedures over the prior year
receivable to test collection rates; and
● Evaluating the application of NZ IFRS 15 against
technical guidance and the accounting standards.
We have no matters to report from the procedures performed
above.

Our audit approach

Overview

Overall group materiality: $467,000, which represents 2.5% of (loss)/earnings
before interest, tax, depreciation and amortisation (EBITDA).
We chose earnings before interest, tax, depreciation and amortisation (EBITDA)
as the benchmark because, in our view, it is the benchmark against which the
performance of the Group is most commonly measured by users, and is a
generally accepted benchmark.
We tailored the scope of our audit in order to perform sufficient work to enable us
to provide an opinion on the consolidated financial statements as a whole, taking
into account the structure of the Group, the accounting processes and controls,
and the industry in which the Group operates.
As reported above, we have one key audit matter, being:
● Determining the timing of revenue recognition for US revenue.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
38




PwC


As part of designing our audit, we determined materiality and assessed the risks of material
misstatement in the consolidated financial statements. In particular, we considered where
management made subjective judgements; for example, in respect of significant accounting estimates
that involved making assumptions and considering future events that are inherently uncertain. As in all
of our audits, we also addressed the risk of management override of internal controls, including among
other matters, consideration of whether there was evidence of bias that represented a risk of material
misstatement due to fraud.
Materiality
The scope of our audit was influenced by our application of materiality. An audit is designed to obtain
reasonable assurance about whether the consolidated financial statements are free from material
misstatement. Misstatements may arise due to fraud or error. They are considered material if,
individually or in aggregate, they could reasonably be expected to influence the economic decisions of
users taken on the basis of the consolidated financial statements.
Based on our professional judgement, we determined certain quantitative thresholds for materiality,
including the overall Group materiality for the consolidated financial statements as a whole as set out
above. These, together with qualitative considerations, helped us to determine the scope of our audit,
the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements, both
individually and in aggregate, on the consolidated financial statements as a whole.
How we tailored our group audit scope
We tailored the scope of our audit in order to perform sufficient work to enable us to provide an opinion
on the consolidated financial statements as a whole, taking into account the structure of the Group, the
accounting processes and controls, and the industry in which the Group operates.
We selected transactions and balances to audit based on their materiality to the Group rather than
determining the scope of procedures to perform by auditing only specific subsidiaries or business
units.
Other information
The Directors are responsible for the other information. The other information comprises the
information included in the Annual report, but does not include the consolidated financial statements
and our auditor's report thereon. The Annual report is expected to be made available to us after the
date of this auditor's report.
Our opinion on the consolidated financial statements does not cover the other information and we will
not express any form of audit opinion or assurance conclusion thereon.
In connection with our audit of the consolidated financial statements, our responsibility is to read the
other information and, in doing so, consider whether the other information is materially inconsistent
with the consolidated financial statements or our knowledge obtained in the audit, or otherwise
appears to be materially misstated.
When we read the other information not yet received, if we conclude that there is a material
misstatement therein, we are required to communicate the matter to the Directors and use our
professional judgement to determine the appropriate action to take.
Responsibilities of the Directors for the consolidated financial statements
The Directors are responsible, on behalf of the Company, for the preparation and fair presentation of
the consolidated financial statements in accordance with NZ IFRS and IFRS, and for such internal
control as the Directors determine is necessary to enable the preparation of consolidated financial
statements that are free from material misstatement, whether due to fraud or error.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
39




PwC


In preparing the consolidated financial statements, the Directors are responsible for assessing the
Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going
concern and using the going concern basis of accounting unless the Directors either intend to liquidate
the Group or to cease operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the consolidated financial statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial
statements, as a whole, are free from material misstatement, whether due to fraud or error, and to
issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance,
but is not a guarantee that an audit conducted in accordance with ISAs (NZ) and ISAs will always
detect a material misstatement when it exists. Misstatements can arise from fraud or error and are
considered material if, individually or in the aggregate, they could reasonably be expected to influence
the economic decisions of users taken on the basis of these consolidated financial statements.
A further description of our responsibilities for the audit of the consolidated financial statements is
located at the External Reporting Board’s website at:
https://www.xrb.govt.nz/assurance-standards/auditors-responsibilities/audit-report-1/
This description forms part of our auditor’s report.
Who we report to
This report is made solely to the Company’s shareholders, as a body. Our audit work has been
undertaken so that we might state those matters which we are required to state to them in an auditor’s
report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the Company and the Company’s shareholders, as a body, for our
audit work, for this report or for the opinions we have formed.

The engagement partner on the audit resulting in this independent auditor’s report is Maxwell John
Dixon.

For and on behalf of:





Chartered Accountants Dunedin
25 May 2022

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2022
40
COMPANY DIRECTORY
As at 31 March 2022
Issued Capital
810,087,233 Ordinary Shares
Registered Office
Anderson Lloyd
Level 10, Otago House
Cnr Moray Place and Princes Street
Dunedin
Directors
C. Gallaher – Chairman
A. Masfen
S. Park
B. Williams
A. Stove
M. Green (appointed 10 May 2021)
T. Barclay (appointed 21 March 2022)
D. Darling (ceased 17 January 2022)
Chief Executive Officer
Peter Meintjes
Nature of Business
Research, develop and commercialise new
diagnostic and prognostic tools for the early
detection and management of cancers.
Auditors
PricewaterhouseCoopers
Dunedin
Bankers
Bank of New Zealand
Dunedin
ANZ
Dunedin
Kiwibank
Dunedin
Westpac
Dunedin
Solicitors
Anderson Lloyd
Level 10, Otago House
Cnr Moray Place and Princes Street
Dunedin
Securities Registrar
Link Market Services Limited
138 Tancred Street
Ashburton
Company Number
1119032
Date of Incorporation
27th February 2001

PACIFIC EDGE COMMUNICATIONS

Websites
www.pacificedgedx.com
www.cxbladder.com
Facebook
www.facebook.com/PacificEdgeLtd
www.facebook.com/Cxbladder

Twitter
@PacificEdgeLtd
@Cxbladder

LinkedIn
www.linkedin.com/company/pacific-edge-ltd

87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
www.pacificedge.co.nz

---

Template
Results announcement
(for Equity Security issuer/Equity and Debt Security issuer)
Updated as at 17 October 2019


Results for announcement to the market
Name of issuer Pacific Edge Limited
Reporting Period 12 months to 31 March 2022
Previous Reporting Period 12 months to 31 March 2021
Currency NZD (New Zealand Dollar)
Amount (000s) Percentage change
Revenue from continuing
operations
$11,445 49% Increase
Total Revenue $13,878 33% Increase
Net profit/(loss) from
continuing operations
($19,788) 39% Decrease
Total net profit/(loss) ($19,788) 39% Decrease
Interim/Final Dividend
Amount per Quoted Equity
Security
The Company does not propose to pay dividends to
shareholders
Imputed amount per Quoted
Equity Security
Not Applicable
Record Date Not Applicable
Dividend Payment Date Not Applicable
Current period Prior comparable period
Net tangible assets per
Quoted Equity Security
$0.133 $0.034
A brief explanation of any of
the figures above necessary
to enable the figures to be
understood
The Results Announcement should be read in conjunction with
the audited consolidated financial statements for the year ended
31 March 2022, the results presentation and commentary, all of
which have been released with this Results Announcement.
Authority for this announcement
Name of person authorised
to make this announcement
Peter Meintjes
Contact person for this
announcement
Peter Meintjes
Contact phone number
+64 (3) 479 5800

Contact email address peter.meintjes@pelnz.com
Date of release through MAP 26/05/2022

Audited financial statements accompany this announcement.